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SUMMARY 
Background:  
A biosimilar is defined as a biologic product that is similar but not identical to the 
reference/originator biologic product. Biologic products have raised hopes of improving 
the quality of life especially in the treatment of chronic non-communicable diseases 
(NCDs). Of all the major health threats to emerge since the start of this century, none has 
challenged the very foundations of public health as profoundly as the rise of NCDs. 
However, the increasing cost of treatment of biologic products has raised many questions 
regarding its access in the context of multiple inequalities. The arrival of the patent cliff in 
this sector has given rise to biosimilars.  
The emergence of biosimilars is expected to go a long way in reducing the cost of care of 
NCDs. The use of biosimilars is based on the assumption that they are of assured quality 
and of the same pharmaceutical standard as the reference biologicals. Their quality should 
therefore be rigorously controlled and assured. Uganda has had biologicals on its market 
that are claimed to be copies of the originator biologicals also known as biosimilars. Most 
of these products have not been approved through a biosimilar approval procedure, but 
have instead been licensed (by the Uganda National Drug Authority (NDA)) using the 
same requirements as generics or small molecule medic ines. According to the World 
Health Organization (WHO) Guidelines on the Evaluation of Similar Biotherapeutic 
Products, a biosimilar that has not been demonstrated to be similar to a reference product 
through head-to-head comparisons should not be describe d as similar or be called a 
biosimilar. Although these products are on the Ugandan market, based on the above, they 
cannot be referred to as biosimilars. In November 2017 however, NDA embarked on the  
process of developing guidelines for assessment of biologics, and a specific guideline for 
assessment of biosimilars. The proposed title for the biosimilar assessment guidelines is; 
‘Guidelines for Registration of Similar Biotherapeutic products .’ The purpose of the 
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research was to assess whether the proposed guideline makes acceptable provision for 
internationally accepted standards of quality, safety and efficacy of biosimilars, and to 
make recommendations for inclusion based on internationally accepted practices.   
Method:  
The study employed the principles of explorative comprehensive literature-based review 
using a thematic qualitative approach. The method of data collection was documentation, 
collected and selected using document review and analysis. Documentation used for the 
research was obtained by internet search, using the google search engine. The method 
chosen was in keeping with the aims and objectives of the study to critically evaluate the 
proposed NDA biosimilar assessment guidelines by comparison of the proposed guidelines 
with those from chosen jurisdictions, i.e. European Union (EU), U.S.A, WHO and South 
Africa; and make recommendations for identified gaps. 
 
Results:  
The key scientific principles for establishing biosimilarity with respect to quality, non-
clinical and clinical requirements, are the same across the chosen jurisdictions and in the 
proposed NDA biosimilar guidelines. They all require establishing biosimilarity using a 
stepwise approach. They require a comprehensive comparison of the quality attributes of 
the biosimilar and reference products. Fulfilment of this requirement then determines the 
need and amount of additional studies required i.e. non-clinical and clinical studies. A risk-
based approach is used to evaluate all data and information in support of the biosimilarity 
of the proposed product. The depth of information included however varies, for example, 
the EU and U.S.A guidelines provide detailed information on the biosimilarity approach in 
comparison to the other jurisdictions. The types of studies at each step are specified in 
detail. In addition, the clinically meaningful differences that would lead to rejection of 
biosimilar applications are well defined.  
Unlike the selected jurisdictions, NDA’s position on reference product requirements, 
extrapolation of indications and interchangeability principles was not stated. 
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Inconsistencies were also found in some sections of the proposed NDA guideline. These 
were highlighted and recommendations provided, for example, inconsistencies were 
observed in the glossary of terms, inclusion of a Public Assessment Summary Information 
for Similar Biotherapeutic Product and not a Summary Information for Similar 
Biotherapeutic Product as mentioned in the guideline among others. Some of the 
recommendations for inclusion based on standards from the chosen jurisdictions are 
included; information on reference product sourcing applicable to Uganda, NDA’s position 
on interchangeability and/or substitution; and on possibility of extrapolation of efficacy and 
safety from one indication to another.    
 
Conclusion:  
Availability of biosimilar assessment guidelines will go a long way in ensuring that NDA 
effectively regulates biosimilars to ensure that only safe, efficacious and good quality 
biosimilars are available on the Ugandan market, and increase confidence in these 
products. The proposed assessment guidelines are comparable with those from the selected 
jurisdictions with respect to the key technical assessment principles. These should therefore 
be finalized with recommended revisions and made available, for example, on the NDA 
website. The recommendations as attached in Appendix I, were shared with NDA.  
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Chapter One: Introduction 
 
Of all the major health threats to emerge since the start of this century, none has challenged the very 
foundations of public health as profoundly as the rise of chronic Non Communicable Diseases (NCDs). 
The prevalence of heart disease, cancer, diabetes, and chronic respiratory diseases, once considered the 
close companions of affluent societies, is now global, with the heaviest burden concentrated in low-and 
middle-income countries1. According to the World Health Organization (WHO), 80% of deaths from 
NCDs now occur in low-and middle-income countries, up from 40% in 1990. By 2030, NCDs will be 
the leading cause of death and disability in every region in the world2. In fact, at the seventy-first World 
Health Assembly meeting held on 24 May 2018, Health Assembly delegates called for stepped up 
action in the global fight to eradicate NCDs, including urging for participation by heads of state and 
government at the Third United Nations General Assembly High-level Meeting on the Prevention and 
Control of NCDs held on 27 September 2018.  
The advent of biologic therapeutic agents more than a decade ago has transformed the treatment of 
NCDs. Despite the benefits of these biologic therapies for treatment of these conditions however, not all 
patients for whom they are indicated receive them mainly because of the high purchase costs involved3.  
Annual costs of many biologics approach or exceed USD100,000, with some up to 22 times more 
expensive than small-molecule drugs4.  However, patents of many biologic medicines have already 
expired or will soon reach their expiry date. This has led to increased interest in the development of 
biosimilars, which are similar to the original biologic agents. According to a country-wise biosimilar 
pipelines number in development worldwide carried out in 2017, China had 269 biosimilars in 
development, which was the largest number, followed by India with 257 biosimilars in development. 
Other countries included USA (187), South Korea (109), Russia (97), Switzerland (57), Argentina (48), 
Japan (45) and Brazil (37)5.  The development of biosimilars after the expiry of patents of the original 
products is expected to make biologics available at more affordable prices and to increase their use by 
http://etd.uwc.ac.za/
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providing more treatment options6. In the United States of America (U.S.A), five-year cost savings of 
USD256 million are estimated with use of filgrastim biosimilar7. 
However, unless their quality, efficacy and safety are assured, biosimilars like any other biologics can 
present with unknown or dire consequences to public health2.  As mentioned above, there are several 
biosimilars under development worldwide. However, some of the countries from which the biosimilars 
are developed do not have stringent regulatory agencies. In several African countries including Uganda, 
lack of relevant competencies for regulation of biologicals and biosimilars resulted in issuance of 
marketing authorization for biosimilars using criteria for generic medicines2.  The lack of appropriate 
regulatory framework has in turn restricted market access to biosimilars. Only few health care providers 
are aware of biosimilars presence in the market. This is attributed to the lack of confidence in efficacy, 
safety and manufacturing process of the biosimilars6, 8.  
Improving access to biosimilars and ensuring they are used appropriately requires a high degree of 
collaboration between various stakeholders, each of which has a distinct role. The main roles of 
regulatory authorities, such as, National Drug Authority (NDA), for example, are to provide regulatory 
oversight of biosimilars throughout their product life-cycle and to ensure that only high-quality; safe 
and efficacious biosimilars are available on the market 6. Like other therapeutic products, biosimilars 
require effective regulatory oversight for the management of the potential risks they pose and to 
maximize their benefits9.  
Uganda’s NDA embarked on the process of developing guidelines for assessment of biologics, and a 
specific guideline for assessment of biosimilars, in November 2017. The proposed title for the 
biosimilar assessment guidelines is; ‘Guidelines for Registration of Similar Biotherapeutic products .’ 
This is the subject matter for this research. At the time of the research, the guideline had not yet been 
finalized.  
The purpose of this research therefore was to assess the current work done in this regard (Current draft – 
May 2018), and make recommendations based on internationally accepted practices from European 
Medicines Agency (EMA), the United States Food and Drugs Administration (US FDA), the World 
Health Organization (WHO), and the South African Health Products Regulatory Authority (SAHPRA), 
guidelines for biosimilars, and also on best practices come across during literature review. 
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Chapter Two: Literature Review 
2.1 Biosimilars 
Biosimilars are biologic products that are similar but not identical to reference/originator biologic 
products. Although described differently by various global health agencies, biosimilars generally are 
large-molecular-weight, complex molecules that are produced in living ce lls through genetic 
engineering10. Biologics differ from conventional small molecule drugs in that they are created from 
living organisms, either naturally or via genetic manipulation (e.g. monoclonal antibodies) or are 
manufactured from complex building blocks of living organisms (e.g. siRNA, aptamers,). In either case, 
they demonstrate considerable molecular complexity and heterogeneity, and are more difficult to 
characterize physico-chemically than synthetic chemical entities. Indeed, some components of a 
finished biologic may be unknown. These large, complex molecules, or mixtures of molecules, are often 
manufactured using recombinant DNA technology. Examples include insulin, growth hormones and 
erthropoietins11. This complexity means that for biologics, the product is the process, and manufacturers 
must use a manufacturing process that remains consistent over time to ensure product consistency, 
quality and purity 11. 
 
In contrast, conventional drugs, chemical entities of low molecular weight typically ranging from 300 to 
600 daltons, are typically produced by chemical synthesis, have well-defined chemical structures and 
can be analysed to identify all components. Drug makers can alter the production process extensively 
and use laboratory test to confirm that the product remains the same11. These differences are reflected 
when branded products are substituted with generics, once patent life has expired, a step that has 
contributed enormously to making many medicines affordable.  
For biologics, demonstration of comparability between different forms of a biological product is very 
demanding because the products cannot be identical, only similar, hence the term ‘biosimilar’ 11. 
 
 
http://etd.uwc.ac.za/
13 
 
 
 
 
Table 2.1: Summary of key differences between bios imilars and generics10, 11 
Biosimilars Generics 
While the primary amino acid backbone of a 
biosimilar protein is identical to that of the reference 
product, the glycosylation pattern will vary with the 
cell type used, and its activity including 
immunogenicity.  
Active substance is similar to the reference and is 
generally administered at the same dose to treat the 
same disease 
Complexity of production makes exact replication of 
the originator molecule virtually unattainable with 
batch-to batch variation  
Same qualitative and quantitative composition with 
respect to active substances as innovator product 
A stepwise approach is used to demonstrate 
biosimilarity between the reference product and 
biosimilar.  
The stepwise demonstration of biosimilarity includes 
in vitro analytical testing, nonclinical comparative 
pharmacology, toxicology, pharmacokinetic (PK)  
testing, and one or more clinical trials to confirm 
quality, efficacy, and safety of the proposed 
biosimilar as compared with the reference product69.  
A direct comparison of the reference product and 
generic medicine is required to claim equivalence. 
Comparison is usually made by an in vivo PK study 
in humans showing that the rate of absorption and 
extent of bioavailability lie within strictly defined 
limits. This is referred to as a bioequivalence study or 
therapeutic equivalence study. 
The different salts, esters, ethers, isomers, mixtures 
of isomers, complexes or derivatives of an active 
substance are considered to be the same active 
substance, unless they differ significantly in 
properties with regard to safety and/or efficacy. 
20-30 % discount over reference product 80-90 % discount over reference product 
$*100 - $200M in development costs $1 - $5M in development costs 
 
8 – 10 year development timeline 
 
3 – 5 year development timeline 
No interchangeability or automatic substitution. 
Scientific justification has to be provided 
Interchangeable with reference product without 
justification 
    *$ is the currency symbol for United States Dollar (USD). 
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2.2 Background to regulation of biosimilars 
Historically, the European regulatory authority, the EMA has taken a global leadership role on 
biosimilar drug development and approval. The WHO and a number of developed and other developing 
nations followed the EMA’s lead by adopting similar principles in their guidelines. Examples of onset 
of biosimilar regulation in different markets were as follows: South Africa (2009), Japan (2009), WHO 
(2010), Canada (2010), USA (2010), New Zealand (2011) and India (2012)12.  
 
An initial unfortunate experience with a biosimilar product in the late 1990s served as an alert to the 
inherent risks of making apparently small changes to a biological product11,13. Hospira’s biosimilar 
epoetin zeta (Retacrit®), was approved by EMA to the reference biologic Eprex® (Amgen/Johnson & 
Johnson), a synthetic erythropoietin (epoetin alpha) used to replace the erythropoietin that is deficient in 
renal failure patients who cannot make enough erythropoietin, and to treat cancer patients developing 
anaemia because of chemotherapy treatment. Whilst preapproval nonclinical in vivo physicochemical 
studies proved epoetin zeta to be biosimilar to Eprex®, clinical trials showed low potency, depicting 
differences in the proteins that are discerned with the available technologies. An unforeseen burst of 
pure red cell aplasia (PRCA) occurred in patients with anaemia of renal failure treated with Eprex® in 
1998. In order to comply with EMA’s request, to minimize the risk of serious infections with proteins of 
human origin, the company replaced human serum albumin (HSA) with polysorbate 80 and glycine as 
stabilizers. The new formulation resulted in the development of antibodies that neutralized both the 
recombinant protein and the native hormone leading to an increase in the frequency of cases with PRCA, 
requiring some patients to have blood transfusions and dialysis. The cause of the pure red cell aplasia 
did not become apparent for some time. Eventually, it was established that the polysorbate 80 leached 
from uncoated rubber bungs in prefilled syringes for subcutaneous injection and behaved as an adjuvant, 
resulting in a greatly enhanced immune reaction to the epoietin alpha. Subsequently, the problem was 
resolved by replacement of the rubber bungs in the prefilled syringes with fluoro-resin coated stoppers  
11,13. 
It is believed, that this statutory lesson perhaps contributed to the rigorous approach of the EMA to 
establishing the similarity of both structure and activity of biosimilars to that the reference product, and 
also for the world to look at biologics and more specifically biosimilars with caution11,13. 
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The goal of the regulatory agencies is to ensure that biosimilars meet high standards of quality, safety, 
and efficacy, and are highly similar to the reference product. However, although there are many 
regulatory guidance documents, there is so far no global consensus on the regulatory pathway for 
biosimilars. Many countries, besides the USA and the European Union (EU), are currently authoring 
guidance documents for biosimilars. Several, including Canada, Brazil, South Africa, Japan, and Korea 
have used the principles for establishing biosimilarity outlined in the WHO guidance documents as a 
platform for authoring their national guidelines (Figure 2.1) 14 
 
Figure 2.1: Evolution of the biosimilars regulatory landscape across the globe . 
 
2.3. Overview of biosimilar regulation in chosen jurisdictions  
Biosimilar regulation in the chosen jurisdictions; EU, South Africa, U.S.A, WHO and Uganda is 
discussed in more detail in the following sections. The rationale for selection of the chosen jurisdictions 
is provided in the Work Plan (Chapter 3).  Information was obtained from the websites of the respective 
agencies responsible for regulation of biosimilars, as applicable. The following information was 
provided for each of the regulatory agencies; responsible agency, regulatory framework, available 
biosimilar guidelines, patent information for reference biotherapeutic products and availability of multi-
stakeholder information (access to biosimilar information).  
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2.3.1. Biosimilar regulation in the EU  
EMA is responsible for evaluating most of applications to market biosimilars in the EU15. As earlier 
mentioned, the EU through EMA pioneered the regulation of biosimilar medicines with the first 
biosimilar (Omnitrope® - biosimilar recombinant human growth hormone [rhGH]; manufactured by 
Sandoz, Kundl, Austria), approved in 200615,16.  Omnitrope® is used to treat growth failure in children 
and adults who lack natural growth hormone, and in those with chronic kidney failure, Noonan  
syndrome, Turner syndrome, short stature at birth with no catch-up growth, and other causes17. EMA 
has acquired over ten years of experience in biosimilars regulation15, 16.  
 
In the EU, biosimilars are approved according to the same standards of pharmaceutical quality, safety 
and efficacy that apply to all biological medicines. Marketing authorization is granted in accordance 
with the provisions of Article 8 of Directive 2001/83/EC, as amended. Specific to biosimilars, the legal 
basis of Article 10(4) of Directive 2001/83/EC and Section 4, Part II, Annex I to the said Directive lays 
down the requirements for the Marketing Authorization Applications (MAAs) based on the 
demonstration of the similar nature of the two biological medicinal products15. 
 
Biosimilars can only be authorized once the patent on the reference biological medicine has expired. 
According to the website, the biological reference medicine must have been authorized for at least eight 
years before another company can apply for approval of a similar biological medicine15. 
 
Information on biosimilars is readily available on the EMA website. EMA has not only published 
guidance and guidelines for biosimilar manufacturers/developers, but has also published information for 
patients and health care professionals to improve understanding of biosimilar medicines in the EU. The 
following information for patients and health care professionals is currently published15:  
• An animated video for patients explaining key facts on biosimilar medicines and how EMA 
works to ensure that they are safe and effective as their reference biological medicines. The 
video is currently available in the following European languages: Dutch, English, French, 
German, Italian, Polish, Portuguese and Spanish. 
http://etd.uwc.ac.za/
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• An information guide for patients published by the European Commission explaining what 
biosimilar medicines are, how they are developed and approved in the EU and what patients can 
expect in terms of availability and safety. The guide is available in 23 official EU languages. 
• Biosimilars in the EU – Information guide for health care professionals. The guide is available in 
eight (8) languages; English, Dutch, French, German, Italian, Polish, Portuguese and Spanish.  
 
In addition, the EU publishes summaries of the European public assessment reports (EPARs) for each of 
the approved biosimilars. The reports explain how EMA assessed the medicine to recommend its 
authorization in the EU and its conditions of use. Product information which provides practical 
information for health care providers and patients is also published for each approved biosimilar. The 
product information includes summary of product characteristics, labelling information and package 
insert or patient information leaflet (PIL) 15.  
 
The EU follows a multidisciplinary approach for biosimilar regulation18. The Committee for Medicinal 
Products for Human Use (CHMP) issues specific guidelines concerning scientific data to be provided to 
substantiate the claim of similarity used as the basis for a MAA for any biological medicinal product. 
Listed below are the scientific guidelines currently published by EMA that assist medicine developers to 
prepare marketing authorization applications for biosimilars 18:  
 
Overarching biosimilar guidelines*: 
1. Similar biological medicinal products – outlines the general principles to be applied for similar 
biological medicinal products 
2. Similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues 
3. Similar biological medicinal products containing biotechnology-derived proteins as active 
substance: quality issues 
 
Product-specific biosimilar guidelines:  
1. Biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor 
(Annex to guideline on similar biological medicinal products containing biotechnology-derived 
proteins as active substance: non-clinical and clinical issues)  
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2. Non-clinical and clinical development of similar biological medicinal products containing low-
molecular-weight heparins 
3. Non-clinical and clinical development of similar biological medicinal products containing 
recombinant human insulin and insulin analogues 
4. Similar biological medicinal products containing interferon beta 
5. Similar biological medicinal products containing monoclonal antibodies: non-clinical and 
clinical issues 
6. Similar biological medicinal products containing recombinant erythropoietins 
7. Similar biological medicinal products containing recombinant follicle-stimulating hormone 
8. Similar medicinal products containing somatropin (Annex to guideline on similar biological 
medicinal products containing biotechnology-derived proteins as active substance : non-clinical 
and clinical issues) 
 
Other guidelines relevant for biosimilars:  
1. Comparability of biotechnology-derived medicinal products after a change in the manufacturing 
process - non-clinical and clinical issues 
2. ICH Q5E Biotechnological/biological products subject to changes in their manufacturing 
process: comparability of biotechnological/biological products 
3. Immunogenicity assessment of biotechnology-derived therapeutic proteins 
4. Immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use 
*Only the overarching biosimilar guidelines were considered and reviewed for this project.  
According to the website, 59 biosimilars have currently been approved by EMA. Information on 
approved products including public assessment reports is available at the following website; 
https://www.ema.europa.eu/en/search/search/search_api_aggregation_ema_medicine_types/field_ema_
med_biosimilar?search_api_views_fulltext=biosimilars%20approved%20by%20EU 
 
2.3.2 Biosimilar regulation in the USA  
In the USA, biosimilars are regulated by the U.S. Food and Drug Administration (FDA)’s Center for 
Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER)19.  
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The FDA approved its first biosimilar, Zarxio® (filgrastim, a recombinant, non-pegylated human 
granulocyte colony stimulating factor [G-CSFT] manufactured by Sandoz) in March 2015. It is used to 
treat low blood neutrophils in the immune compromised, for example in AIDs patients, following 
chemotherapy or radiation poisoning20. 
 
Marketing authorization for biosimilars is granted in accordance with the provisions of section 351 (k) 
of the Public Health Service Act (PHS Act). The Biologics Price Competition and Innovation Act of 
2009 (BPCI) was enacted as part of the Patient Protection and Affordable Care Act (Affordable Care 
Act) (Public Law 111-148) on 23 March 2010. The BPCI Act amends the PHS Act and other statutes to 
create an abbreviated licensure pathway in section 351(k) of the PHS Act for biological products shown 
to be biosimilar to or interchangeable with an FDA-licensed biological reference product (sections 7001 
through 7003 of the Patient Protection and Affordable Care Act (Affordable Care Act)19. 
 
Section 351(k) of the PHS Act, entitled “Exclusivity for Reference Product,” has the following 
provisions; “approval of a 351(k) application may not be made effective until 12 years after the date of 
first licensure of the reference product (statute excludes the date of licensure of supplements and certain 
applications); A 351(k) application for a biosimilar or interchangeable biological product cannot be 
submitted for review  until 4 years after the date on which the reference product was first licensed under 
section 351(a) of the PHS Act.” As provided by section 351(m) of the PHS Act, an additional six-month 
period of exclusivity (in which a biosimilar or interchangeable biological product cannot be licensed or 
accepted for review) will attach to the 12- and 4-year periods, respectively, if the sponsor conducts 
pediatric studies that meet the requirements for pediatric exclusivity pursuant to section 505A of the 
Federal Food, Drug, and Cosmetic Act (FD&C Act).  Furthermore, a biological  product seeking 
licensure as biosimilar to or interchangeable with a reference product indicated for a rare disease or 
condition and granted 7 years of “orphan drug exclusivity” under section  527(a) of the FD&C Act, may 
not be licensed by FDA for the protected orphan indication until  after the expiration of the 7-year 
orphan drug exclusivity period or the 12-year reference product  exclusivity period granted under 
section 351(k)(7) of the PHS Act, whichever is later 19. 
 
Information on biosimilars is readily available on the U.S.FDA website19. In addition to the various 
guidances listed below, U.S.FDA published a Biosimilars Action Plan (BAP) to provide information 
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about the key actions the agency is taking to encourage innovation and competition among biologics 
and the development of biosimilars. Also, through its Center of Drug Evaluation and Research (CDER), 
the FDA offers a variety of patient and prescriber outreach materials including: videos [The Promise of 
Biosimilars, The Basics of Biosimilars, The Concept of Interchangeability, The Biosimilar 
Development Process, and Analytical Data for Biosimilar Products]; Fact sheets [Biological Product 
Definitions, Biosimilar Product Regulatory Review and Approval, Prescribing Biosimilar Products, and 
Prescribing Interchangeable Products]; Infographics [Biosimilar Development Process, and What is a 
Biosimilar]; and stakeholder toolkit intended to help stakeholders promote FDA as a  resource for 
information on biosimilars and interchangeable products and to encourage prescribers and patients to 
talk to each other about these medicines. The stakeholder kit includes: animated GIFs, website badges, 
print Ads, infocards, twitter posts and facebook/LinkedIn posts.  
The website also includes drop-in content e.g. newsletter articles for prescribers and patients related to 
biosimilars. In addition to the above, the FDA offers online courses, webinars and presentations (FDA 
staff presentations) to help manufactures, the public and regulators worldwide learn more about 
biologics, biosimilars and interchangeable products. Product information, that is, prescribing 
information and any other related information e.g. press releases is available for each of the approved 
biosimilar medicines19. 
 
Below are the scientific guidelines currently published by U.S.FDA intended to help medicine 
developers prepare marketing authorization applications for biosimilars19: 
1. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product ; final (2015)** 
2. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a 
Reference Product; final (2015)** 
3. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, 
final (2016)** 
4. Reference Product Exclusivity for Biological Products Filed Under; draft (2014) 
5. New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2); draft 
(2018) 
6. Questions and Answers on Biosimilar Development and the BPCI Act, final (2018) 
7. Considerations in Demonstrating Interchangeability With a Reference Product Guidance for 
Industry, draft (2017) 
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8. Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance 
for Industry, draft (2018) 
**These guidelines were considered and reviewed for the project. 
 
Table 2.2: U.S.FDA has currently approved 17 biosimilars as shown in the list below19, 21 
Product Name  Approval Date  
Zarxio  (filgrastim-sndz) March 2015 
Inflectra (infliximab-dyyb) 
April 2016 
 
Erelzi (etanercept-szzs) August  2016 
Amjevita (adalimumab -atto) September 2016 
Renflexis (infliximab-abda) May 2017 
Cyltezo (adalimumab-adbm) August 2017 
Mvasi (bevacizumab-awwb) September 2017 
Ogivri (trastuzumab-dkst) December 2017 
Ixifi (infliximab-qbtx) December 2017 
Retacrit (epoetin alfa-epbx) May 2018 
Fulphila (pegfilgrastim-jmdb) June 2018 
Nivestym (filgrastim-aafi) July 2018 
Hyrimoz (adalimumab-adaz) October  2018 
Udenyca (pegfilgrastim-cbqv)  November 2018 
Truxima (rituximab-abbs) November 2018 
Herzuma  (trastuzumab-pkrb)  December 2018 
Ontruzant (trastuzumab-dttb) January 2019 
 
2.3.3 Biosimilar regulation by the WHO  
The WHO is not a drug regulatory agency although it has unique regulatory roles. One of WHO’s 
mandates is to aid member states to strengthen regulation, including post-marketing surveillance, and to 
eliminate substandard and falsified medicines22. In as far as regulation is concerned, WHO currently has 
the following roles listed below for ease of reference22; 
• Developing international norms, standards and guidelines to ensure that countries worldwide 
can regulate health products and technologies consistently. Norms, guidelines and standards 
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have been developed for biologicals including biosimilars, blood products, International 
Nonproprietary Names (INNs), Quality assurance including of medicinal products, and 
immunization standards 
• Regulatory system strengthening (RSS). RSS helps member states through a variety of 
approaches including: assessment of regulatory functions using a standardized tool*** and the 
creation of an institutional development plan (IDP) designed to bring each NRA up to 
benchmarked international standards; direct technical assistance based on country IDPs; and 
support for information and work-sharing arrangements made possible through the 
implementation of harmonized standards and best practices and the creation of regional and 
global regulatory networks (WHO collaborative procedure). 
***The WHO Global Benchmarking Tool (GBT) helps measure national regulatory systems against defined indicators in order to ident ify 
areas for improvement in the form of IDPs. A key objective of the benchmarking process is to help regulatory authorities, particularly 
those in low- and middle-income countries, reach a level of maturity commensurate with a stable well-functioning and integrated system of 
oversight for medical products (Maturity Level 3). 
• Promoting global safety of medical products by coordinating global networks for information 
sharing, such as data bases and monitoring and alert systems, and by supporting countries to 
develop national capacities for the post-marketing surveillance of health products. 
• Prequalification of medicines23. The WHO Prequalification Team (WHO PQT) was formed 
with the aim of guiding UN agencies and other international organizations with respect to the 
quality of antiretroviral medicines, for supply to low-income countries. Currently, its services 
cover assessment for a range of finished pharmaceutical products (FPP), in several therapeutic 
areas: HIV/AIDS, tuberculosis, malaria, hepatitis (B & C), diarrhoea (specifically zinc 
products), neglected tropical diseases, influenzae and reproductive health conditions) and 
assessment of active pharmaceutical ingredients (API). It carries out inspection of FPP, API, 
clinical sites and quality control laboratories. It also provides technical assistance, and conducts 
extensive training activities.   
According to the WHO website24, in order to explore options to facilitate access to safe, 
effective and quality assured biotherapeutics and biosimilars, the WHO on 05 July 2018 
launched a pilot project to prequalify selected biologics and biosimilars, as a step forward to 
support national and global efforts to increase access to and the affordability of these products. 
This followed the World Health Assembly (WHA) adoption of Resolution WHA67.21 on 
“Access to biotherapeutic products, including biotherapeutic products (biosimilars), and 
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ensuring their quality, safety and efficacy”. Like the Prequalification of medicines program 
which was established in 200125, the pilot project is aimed at working in close cooperation with 
national regulatory agencies and partner organizations to make quality priority biotherapeutics 
and biosimilars available for those who urgently need them. 
WHO has currently invited manufacturers to submit applications for prequalification of two 
biotherapeutic products in the WHO Essential Medicines List: rituximab (used principally to 
treat non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia), and trastuzumab (used to 
treat breast cancer) and their corresponding similar biotherapeutic products. 
   
In 2009, the WHO issued its first guidance, the Guidelines on evaluation of similar Biotherapeutic 
Products (SBPs), Annex 2, Technical Report Series No. 977, 2009 . It has since issued additional 
publications related to biosimilars, intended to give guidance to manufacturers and medicine regulators. 
Listed below is the list of available guidances22,23;  
• 1st invitation for expression of interest to manufacturers of biotherapeutic products and 
biosimilars 
• WHO pilot procedure for prequalification of biotherapeutic products: rituximab and trastuzumab 
• WHO guidelines on submission of documentation for the pilot procedure for prequalification of 
similar biotherapeutic products for rituximab and trastuzumab. Preparation of product dossiers in 
common technical document format – Full Assessment**** 
• WHO guidelines on submission of documentation for the pilot procedure for prequalification of 
rituximab and trastuzumab approved by stringent regulatory authorities (SRA) – Abridged 
assessment 
• Quality Information Summary (QIS) of the biotherapeutic product approved by SRA. 
• Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, Technical Report 
Series No. 977, 2009**** 
 
• Post ECBS 2018 - WHO Questions and Answers: Similar Biotherapeutic Products 
 
• Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs), 
Annex 2, Technical Report Series No. 1004, 2016 
 
**** These guidelines were considered and reviewed for this research project. 
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2.3.4. Biosimilar regulation in South Africa 
Biosimilars in South Africa are regulated by the South African Health Products Regulatory Authority 
(SAHPRA), formerly known as the Medicines Control Council (MCC)26. According to the information 
in the guidelines, marketing authorization of biosimilars is granted based on the provisions in the 
Medicines and Related Substance Act, 1965 (Act 101 of 1965), as amended and the relevant regulations  
26. 
 
Until 2018, there were no statutory provisions in South African patent law or medicines regulatory laws 
dealing specifically with data exclusivity. There were however provisions in the medicines regulatory 
law, and other legislation, which deal with the protection of confidential (such as trade secret) 
information27. However, in 2018 the South African government adopted the Intellectual Property 
Policy which gives effect to the 2001 Doha Declaration on the TRIPS (Trade-Related Aspects of 
Intellectual Property Rights). The policy is expected to lay the groundwork for regulations to be put in 
place and laws to be passed to give effect to intellectual property reform in South Africa28,29.  There is 
currently no exclusivity period requirement for reference products by SAHPRA. 
 
According to the SAHPRA website, the available guideline is the 2014 Biosimilar medicines quality, 
non-clinical and clinical requirements26. It is intended to provide recommendations to applicants 
wishing to submit applications for the registration of biosimilar medicines26. Information on approved 
biosimilars was not available on the SAHPRA website.  
 
2.3.5 Biosimilar regulation in Uganda 
Biosimilars in Uganda are regulated by the NDA30. 
 
According to the information in the proposed guidelines, marketing authorization for biosimilars in 
Uganda is granted in accordance with the provisions of sections 35(1)(a) and 35(3) of the National Drug 
Policy and Authority Act Cap 20630.  Currently, Uganda has no guidelines for biosimilars. The proposed 
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guidelines; Guidelines for Registration of Similar Biotherapeutic Products, May 2018 are yet to be 
finalized. These are the subject of this research and have been attached as appendix III.  
 
Currently, there are no statutory provisions in Uganda patent law or medicines regulatory laws dealing 
specifically with data exclusivity of medicinal products. Although Uganda signed the TRIPS agreement 
with the World Trade Organization (WTO) in 1995, it has not incorporated the flexibilities and 
safeguards into national law. A respective amendment was drafted in 2004 but has not yet been 
approved by the Ugandan Parliament31.  
 
There is currently no information on biosimilars on the NDA website. A separate list of approved 
biosimilars is also not available. Biosimilars and biological medicines are listed along with other 
medicine categories including generics in the human drug register published on the website. It is 
updated on a monthly basis. From the register, it is not possible to filter out biosimilars since there is 
neither provision for therapeutic class or group or pharmacologica l/biotechnology classification. 
However, the list of currently approved/registered biosimilars was requested for and obtained from 
NDA’s Product Assessment and Registration (PAR) department via email, a copy of which was 
included in Appendix II. Currently 30 biosimilars are registered by NDA as per the Table 2.3. 
 
Table 2.3: List of biosimilars registered in Uganda as of 02 February 2019 
Product Name  Year of registration  
Repoitin Injection 2000, Recombinant Human Erythropoietin (rHuEPO) 2012 
Insugen R [Regular], Human Insulin 2012 
Insugen N [N.P.H], Human Insulin 2012 
Insugen -30/70, Human Insulin 2012 
Repoitin Injection 2000, (rHuEPO) 2013 
Heparin, unfractionated heparin (UFH) 2014 
Insuman Comb 30, Human Insulin 2014 
Levemir Flexpen 100u/ml, Human Insulin 2014 
Novomix 30 Flexpen, Human Insulin 2014 
NovoRapid Flexpen, Human Insulin 2014 
Lomoh -80, Enoxaparin sodium 2014 
Isuman Rapid 100IU/ml, Human Insulin 2015 
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Gonal-F 300 IU, Follitropin alfa, 300 IU/0,5 ml (22 µg/0,5 ml) 2015 
Gonal-F 450 IU, Follitropin alfa, 450 IU/0,75 ml (33 µg/0,75 ml) 2015 
Gonal- F 900 IU, Follitropin alfa, 900 IU/1,5 ml (66 µg/1,5 ml) 2015 
Gonal -75 IU, Follitropin alfa, 75 iu (5.5 µg) 2016 
Foligraf 75 I.U, Follicle stimulating hormone 2016 
Lioton Gel, UFH 2016 
Endulin Vial™, Insulin Glargine 100 IU/ Ml 2016 
Endulin Vial™_ 1 vial of 3 ml, Insulin Glargine 100 IU/ Ml 2016 
Endulin Cart™_3 mL cartridge, Insulin Glargine 100 IU/ Ml 2016 
HuCoG-5000 HP, Chorionic gonadotrophin  2017 
U-TRYP 100,000 I.U., Ulinastatin 2017 
Lantus SOLOSTAR in a 3ml cartridge, Insulin Glargine 2017 
Lantus solution for injection, 10ml vial, Insulin Glargine 2017 
Lantus Solostar, Insulin Glargine 2017 
 
2.4 Comparison of biosimilar guidelines  
Sharma et al (2015) 12 provided an overview on the onset of biosimilar regulation in different markets 
with EMA having drafted its first set of guidelines in 2005. According to the publication, the WHO and 
a number of developed and other developing nations followed the EMA’s lead by adopting similar 
principles in their guidelines. Examples of onset of biosimilar regulation in different markets were as 
follows: South Africa (2009), Japan (2009), WHO (2010), Canada (2010), USA (2010), New Zealand 
(2011) and India (2012). At the time of publication, Russia and China neither had specific regulations 
nor guidelines. Additionally, it was found out that the following countries regulated biosimilars in the 
same way as they did new biological products: Philippines, Taiwan, Indonesia and Thailand. 
A presentation by Dr. Kamali Chance made at the Third International Conference and Exhibition on 
Biowavers, Biologics and Biosimilars, that lasted from October 27-29, 2014, in Hyderabad, India32 
focused on comparison of EU (EMA) and US (US FDA) guidelines. According to the presentation, it 
was concluded that both guidelines shared similarities with respect to requirements for the reference 
product(s), a step-wise development approach i.e. each step of development should demonstrate 
acceptable similarity before proceeding to the next and need for a pharmacovigilance plan. It was 
concluded that both guidelines employ a risk-based approach in biosimilar product approval. However, 
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it was noted that the guidelines differed in their requirement for interchangeability, transition study, 
paediatric study assessment, and had different exclusivity periods for innovator biologics and for the 
first interchangeable product. For example, the US FDA provides for interchanging or substitution of 
the biosimilar and reference product without the intervention of the health care provider who prescribed 
the reference product, provided satisfactory justification is submitted. EMA however does not determine 
interchangeability or subsititution. The decision is left to the EU member states; The US FDA 
biosimilar guidances provided for paediatric study assessment whereas the EMA guidances did not.   
 
Kirchoff CF et al (2017)14 discussed the challenges faced by pharmaceutical companies in the 
development of biosimilars. However, the publication also compared in detail EU EMA, US FDA and 
WHO requirements for selection of reference products, manufacturing requirement of biosimilars, the 
role of comparative in vivo non-clinical studies and scientific principles of extrapolation across 
indications.  
Under manufacturing, both EMA and FDA allowed for advancements in formulation science to be 
incorporated in the biosimilar presentation i.e., the formulation excipients in the biosimilar may differ 
from those of the reference product, and, assessments are undertaken to elucidate any relevant effects of 
the revised formulation on the stability, physicochemical and functional characteristics of biosimilars14. 
On the role of comparative in vivo non clinical studies, although the global guidelines on biosimilar 
development were largely aligned in terms of the analytical and clinical aspects, there was substantial 
variability in the amount and type of in vivo nonclinical data required, with the EMA guidelines 
recommending minimal to no use of in vivo assays whereas other countries, such as Japan and China, 
Canada, required more extensive toxicity studies14. 
On the scientific principles of extrapolation across indications, although the decision to extrapolate data 
from one indication to another was made on a case-by-case basis, with strong scientific justification, 
based on the totality of evidence; the concepts were supported by the EMA and the USFDA regulatory 
guidelines14. 
IIiach et al (2017)33 focused on the current biosimilars landscape and discussed how the biosimilars 
pipeline was impacted by regulatory requirements in Canada, EU and the U.S. The discussion focused 
on comparison of the following within the three (3) jurisdictions: current biosimilar landscape, 
biosimilars development, and current uncertainties in regulatory requirements. 
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According to the publication, as earlier mentioned, the EU was leading the way with the largest number 
of regulatory approvals and the most extensive regulatory guidance, followed by Canada and, lastly the 
U.S. The following were identified as factors that could have led to delays in more approvals in these 
regions: capital required to conduct biosimilar trials, innovative strategies to delay the acceptance of 
biosimilars, litigation (especially in the U.S.), and lack of regulatory guidance around substitution33. 
Another key factor that was identified as requiring greater clarity was the acceptance of reference 
products from different jurisdictions, and harmonization of the approach on interchangeability 33. 
 
According to the Derbyshire (2014) article34, a detailed comparison of biosimilar guidelines issued in 
Canada, the EU, Japan and Korea, and by the WHO was provided. In the article, the author noted that 
the clarity of the various guide lines is variable and the regulatory pathways were diverse, with 
agreement on how to define biosimilars differing sometimes significantly between different countries 
and regions. The author therefore recommended harmonization of regulatory standards for biosimilars 
would be of great advantage to biosimilar manufacturers. This would enable them to reduce costs and 
create a level playing field for manufacturers from different countries/regions. The development of a 
global reference product would also be of great advantage, as this would allow manufacturers to reduce 
the number of trials required for global approval 34. 
2.5 Challenges in regulation of biosimilars   
A presentation made by Hudu Mogtari2 in Cape Town, South Africa at the 17th International 
Conference on Drug Regulatory Authorities (ICDRA) that lasted from 27 November to 02 December 
2016, highlighted that several African countries lack relevant competencies including specific 
guidance’s for regulation of biologicals and biosimilars. This has resulted in issuance of marketing 
authorization for biosimilars using criteria for generic medicines, inability to conduct 
pharmacovigilance hence missing important signals, inability to carry out relevant post market 
surveillance (PMS) and Good manufacturing/handling practices inspections, treating large molecules 
(biologics) like small molecules (drugs) and ignoring the potential hazards of biosimilars.  The issues 
raised by Mogtari (2016) were further highlighted by Kang et al (2018)35.The article which focused on 
the discussion of factors that give rise to barriers to market access for biosimilars; and explained the role 
of regulators and the importance of regulatory oversight throughout the product life-cycle of biosimilars; 
noted that some countries have biotherepautics on their markets that are claimed to be copies of original 
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products (i.e.so-called non-innovator or copy-version products). These medicines have not been 
approved through a biosimilar approval procedure but have, instead, been licensed as generics or small-
molecule medicines. As stated in WHO’s guidelines on the evaluation of similar biotherapeutic products, 
a biosimilar that has not been demonstrated to be similar to a reference product through head-to-head 
comparisons with a reference biotherapeutic product should not be described as similar or be called a 
biosimilar. Such products could be licensed using more extensive nonclinical and clinical data sets or 
full licensing applications35. 
 
In other countries e.g. Lebanon, only drafts of regulatory guidelines for registration of biosimilars are 
available8. The publication Review and results about biosimilars prescription and challenges in the 
Middle East and North Africa region8 attributes this lack of clear regulation to the fact that only a few 
physicians or health care providers are aware of biosimilars presence and as such hardly prescribe them 
in Lebanon and in the Arab region. 
 
H.Sharma et al (2015)12 highlighted challenges in the regulation of biosimilars in regions with 
established biosimilars regulation guidelines as mentioned under 2.4: differences in legal framework in 
different countries; lack of consensus across regions on acceptable pathway and parameters if the 
reference product is sourced outside own region; likely differences in the approved formulation and/or 
presentations of the reference product(s) internationally; lack of comprehensive guidance and consensus 
on the application of the most sensitive disease model (in testing of biosimilars) with respect to an 
indication not globally licensed being the most sensitive model; difference in regulatory opinions on 
assessment of similarity through acceptable endpoints and equivalent margins; and lack of acceptance 
of extrapolation across indications in different therapeutic areas by all regulatory agencies globally.  
 
Similarly, Kirchoff CF et al (2017)14 reported that regional and country specific biosimilar pathway 
legislation and guidances are at different stages of development and implementation as presented in 
figure 2.1. As a result, there is no global harmonization on certain aspects of biosimilar development, 
including as mentioned above; the selection of the reference product, nomenclature, and the design of 
analytical, non-clinical, or clinical comparative studies.  
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On the issue of interchangeability of biosimilars, there are major differences between Europe and the 
US when it comes to how they view interchangeability of biosimilars. Although EMA and FDA are 
aligned in most aspects of the concept of biosimilarity; the difference related to ‘interchangeability’ is 
attributed to a discrepancy in terminology and legal definition. In Europe, interchangeability is a 
scientific and medical term that refers to the medical practice of changing one medicine for another that 
is expected to achieve the same clinical outcome. The administrative practice of switching or 
substituting is a national decision. In the US, however, the legal definition of ‘interchangeability’ allows 
for substitution of the biosimilar for the reference product without the intervention of the prescriber36. 
 
 
2.6 Way forward 
Kang et al (2018)35 noted that the main roles of regulatory authorities, for example, are to provide 
regulatory oversight of biosimilars throughout their product life-cycle and to ensure that only high-
quality, safe and efficacious biosimilars are available on the market. This could be achieved by 
increasing the capacity of regulatory authorities. It was however noted that this is particularly 
challenging in resource –limited settings and therefore recommended that regulatory authorities in these 
settings consider establishing regulatory procedures that improve the efficiency of the approval process. 
For example, the established WHO global standards to ensure the quality, safety and efficacy of 
biotherapeutics, including biosimilars, at all stages of their life-cycle, could serve as a basis for mutual 
recognition of regulatory oversight and for regulatory convergence at the global level.  
 
Harmonization of guidelines as the global biosimilar market continues to grow was proposed in a 
number of publications2, 12, 14, 34.  
Efforts are already being made to ensure regulatory harmonization of biosimilar requirements. A 
regulators forum37, the International Pharmaceutical Regulators Forum (IPRF) was created, as a safe 
harbor for discussion and promotion of harmonization among its members. Its membership is composed 
of regulatory authorities and agencies, regional harmonization initiatives and the WHO as indicated in 
table 2.4.  
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Table 2.4: Membership of the IPRF 
Membership type Members 
Regulatory Authorities and Agencies • Australia - Therapeutic Goods Administration (TGA) 
• Brazil - Brazilian Health Surveillance Agency (Anvisa) 
• Canada - Health Canada, Health Products and Food Branch 
• European Union – EMA and Directorate –General for Health and 
Consumers (SANTE) 
• Japan - Ministry of Health, Labour and Welfare, and 
Pharmaceuticals and Medical Devices Agency 
• Kazakhstan – National Center for Expertise 
• Republic of Korea – Ministry of Food and Drug Safety 
• Mexico – COFEPRIS (The Federation Commission for the 
Protection against Sanitary Risk) 
• Russia - Roszdravnadzor (Federal Service for Control over 
Healthcare and Social Development) 
• Singapore - Health Sciences Authority (HSA) 
• Switzerland - Swissmedic, Swiss Institute of Therapeutic 
Products 
• United States of America – U.S FDA 
 
Regional Harmonization Initiatives • ASPEC - (Asia-Pacific Economic Cooperation)  
• ASEAN - (The Association of Southeast Asian Nations) 
• EAC – (East African Community) 
• GCC (Cooperation Council for the Arab States of the Gulf) 
• PANDRH (Pan American Network for Drug Regulatory 
Harmonization) 
• SADC (Southern African Development Community) 
WHO 
 
As mentioned above, one of the objectives of the IPRF is to identify the need for harmonization or 
regulatory convergence, as well as for regulatory cooperation, including work sharing, in specific areas. 
Several working groups are already in operation including the Biosimilars Working Group (BWG). The 
Biosimilars Working Group which is composed of international regulatory authorities has the following 
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objectives; for regulatory convergence of technical requirements for biosimilar products in facilitating 
the regulatory process; and to support international regulators develop safe and effective regulatory 
frameworks for biosimilar products.  
The IPRF BWG has so far published a Public Assessment Summary Information for Biosimilar (PASIB) 
dated 18 August 2016, intended to increase transparency and to facilitate the transition from a local 
assessment report to one prepared in the English language; and a Reflection Paper on Extrapolation of 
Indications in Authorization of Biosimilar Products dated 25 September 2017. The purpose of the 
reflection paper was to communicate the current thinking of various regulatory authorities of different 
regions with respect to the extrapolation of indications from the reference product to the biosimilar 
during the development of these products. It explored the issues associated with the use of extrapolation 
when authorizing biosimilar products for certain indications and proposed principles for the use of 
extrapolation in this context.  
 
In an effort to create patient and healthcare professionals’ awareness of biosimilars, on 13 September 
2018, the European Medicines Agency (EMA) and the European Commission published new material, 
including an animated video for patients that explain key facts on biosimilars and how EMA works to 
ensure that they are as safe and effective as their reference biologicals. The video is available in eight 
European languages: Dutch, English, French, German, Italian, Polish, Portuguese and Spanish. In 
addition, EMA published translations of the biosimilar guide for healthcare professionals into Dutch, 
French, German, Italian, Polish, Portuguese and Spanish. The guide, which was first made available in 
English in 2017, provides healthcare professionals with comprehensive and easily understandable 
information on both the science and the regulat ion underpinning the use of biosimilars. These newly 
published materials complement the Questions & Answers on Biosimilars for patients, which were 
published in 23 EU languages in 201738. 
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Chapter Three: Work plan 
 
3.1 Research question 
 
Are the proposed biosimilars assessment guidelines of the NDA comparable to the EMA, WHO, 
USFDA and SAHPRA guidelines? 
3.2 Aim 
 
The aim of this study was to evaluate the current work done by NDA in development of biosimilars 
assessment (May 2018 draft) which started in November 2017, and make recommendations for 
inclusion based on WHO, EMA, US FDA and SAHPRA guidelines for biosimilars. 
 
3.3 Objectives 
 
The following were the research objectives: 
 
1. To review the biosimilar assessment guidelines of the EMA, FDA, WHO and SAHPRA. 
2. To compare the proposed NDA biosimilar assessment guidelines against those of EMA, FDA, 
WHO and SAHPRA 
3. To review the proposed NDA guidelines generally to identify gaps or inconsistencies, if any 
4. To make recommendations and inform NDA of areas for improvement within the guideline, and 
also based on best regulatory practices come across during literature review. 
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3.4 Rationale for chosen jurisdictions  
3.4.1 EU 
The biosimilars approval pathway was pioneered in the European Union (EU). The EU is by far the 
most advanced in the regulation of biosimilars, and has the best established framework for approval of 
biosimilars, being the first to create guidelines for these products. In the European Union (EU), the legal 
framework for approving biosimilars was established in 2003.  
The EU biosimilars guidelines have formed the basis for development of biosimilars regulations in other 
highly regulated countries/regions e.g. Japan39 and other countries e.g. China40 
3.4.2 WHO 
The Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), WHO 2009, are intended to 
provide globally acceptable principles for licensing biotherapeutic products that are claimed to be 
similar to biotherapeutic products of assured quality, safety, and efficacy that have been licensed based 
on a full licensing dossier. The Guidelines can be adopted as a whole, or partially, by NRAs worldwide 
or used as a basis for establishing national regulatory frameworks for licensure of these products.  
Several countries including Canada, Brazil, South Africa, Japan, and Korea have used the principles for 
establishing biosimilarity outlined in the WHO guidance documents as a platform for authoring their 
national guidelines14. 
 
The WHO has a constitutional mandate to act as the directing and coordinating authority on 
international health work; and to develop, establish and promote international standards for food 
biological, pharmaceutical and similar products41. WHO through the Essential Medicines Program 
(EMP) works at country level, as well as regionally and globally, to support with norm setting and 
regulatory strengthening, and national level technical assistance and training. In the area of biosimilars, 
WHO is supporting countries in establishing the regulatory framework resources, and capacity to 
evaluate biosimilars, facilitate their uptake, and conduct post-marketing monitoring42.  In addition, as 
mentioned in section 2.3.3, the WHO recently launched a pilot project to prequalify selected biologics 
and biosimilars, as a step forward to support national and global efforts to increase access to and the 
affordability of these products24. 
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3.4.3 U.S.A 
The U.S FDA is the largest of the world’s drug regulatory agencies, according to information on the 
ICH website43.  Although the US lags behind the EU with respect to biosimilars regulation, it has 
developed extensive guidances on the regulatory requirements for the evaluation of biosimilars14. 
3.4.4 South Africa 
South Africa was included to provide compar ison with an African national medicines regulatory agency 
(NMRA). According to the ICH website, South Africa’s SAHPRA is the first and currently the only 
African NMRA to obtain ICH observer status which is a step towards achieving membership status44. It 
was stated that becoming a member of the ICH Association sends a clear message that the regulatory 
authority and the regulated industry are committed to align with the highest global standards for the 
quality, efficacy and safety of medicinal products. Membership in ICH brings with it integrity and 
recognition worldwide45. 
Since information on biosimilars regulation in Africa with respect to status in the different NMRAs, was 
not readily available, the fact that South Africa has ICH observer status and that biosimilar guidelines 
are readily available online, contributed to its selection.  
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Chapter Four: Methodology 
 
4.1 Introduction 
The two main types of research design methods are qualitative and quantitative methods. The simple 
distinction between the two methods is that qualitative data analysis deals with the analysis of 
subjective and non-numerical data while quantitative data analysis focuses on analyzing data through a 
numerical or statistical means46. Quantitative methods are used to examine the relationship between 
variables with the primary goal being to analyze and represent that relationship mathematically through 
statistical analysis.  This is the type of research approach most commonly used in scientific research 
problems 46. 
Qualitative methods are chosen when the goal of the research problem is to examine, understand and 
describe a phenomenon.  These methods are a common choice in social science research problems and 
are often used to study ideas, beliefs, human behaviors and other research questions that do not involve 
studying the relationship between variables46. 
Therefore, it is often said that quantitative research seeks to explain and qualitative research seeks to 
understand46.  
 
The purpose of the research was to assess the current work done in the development of biosimilar 
guidelines by NDA, Uganda, and make recommendations for inclusion mainly based on the EU, South 
African, U.S.A and WHO biosimilar guidelines. It was exploratory in nature and sought to examine and 
understand the works done by NDA this far. The data is non-numerical and the research is qualitative in 
nature. 
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4.1.1 Qualitative research methods 
There are five main types of qualitative research designs commonly used: narrative, phenomenology, 
grounded theory, ethnography and case study46. 
 
Table 4.1: Summary of qualitative research approaches and their characteristics 46 
 Narrative Phenomenology Grounded 
Theory 
Ethnography Case study 
Focus Explores the life 
of an individual; 
tells the story 
Attempts to 
understand or 
explain life 
experiences or a 
phenomena 
Investigates 
process, action or 
interaction with 
goal of 
developing a 
theory “grounded 
in observations 
Describes and 
interpretes ethnic, 
cultural, or social 
group 
Examines 
episodic event in 
a definable 
framework; 
develops in depth 
analysis single or 
multiple cases; 
generally 
explaining “how” 
Data collection Interviews and 
documents 
Prmarily through 
interviews, 
sometimes 
observation 
Interviews with 
20-30 individuals 
to gather enough 
data 
Interviews, 
observations, and 
immersion into 
the cultural as an 
active participant  
Documents of the 
case, archives, 
interviews, 
observations, 
physical artifacts 
Data analysis Stories , review of 
historical content, 
development of 
themes 
Study and 
describe 
experiences, 
examine meaning 
and context, look 
for themes, 
classify 
Open, axial, and 
selective coding 
used to categorize 
the data and 
describe the 
implications of 
the categories 
Describe and 
interpret findings 
by analyzing data 
and developing 
themes 
Develop a 
detailed analysis; 
identify themes; 
make assertions 
Written 
Report Form 
Detailed picture 
of person’s life; 
often a 
chronology or 
biography 
Report of 
“essence” of the 
experience, 
description of the 
context of the 
experience or 
phenomena 
Results in a 
theory, theoretical 
model, or figure 
that represents the 
phenomena 
Description of the 
cultural behaviour 
of a group 
In-depth study of 
a case that 
describes the 
case, its themes, 
and possible 
lessons learned 
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The research followed the case study approach based on a comprehensive literature review. The 
narrative, phenomenology, grounded theory and ethnography approaches focus on telling a story; 
understand a phenomena; investigation of an action with the goal of developing a theory; and describe 
and interpret ethnic cultural or social groups respectively, none of which was the focus of the research. 
The purpose of the research was to evaluate and assess critically the NDA draft biosimilar guideline 
which was in line with the case study approach. 
Case studies are analyses of persons, events, decisions, periods, projects, policies, institutions, or other 
systems that are studied holistically by one or more methods. The case study can be done in social 
sciences and life sciences. Case studies may be descriptive or explanatory. Like surveys, case study 
research approaches can be treated as a qualitative or quantitative47.  
A comprehensive literature-based review is described as “an iterative, thematic approach to research 
where qualitative analysis is used to classify information contained in literature and come to a 
conclusion on the basis of qualitative description”4849. Qualitative analysis has value in comparing 
literature, analyzing and proposing alternative strategies48. Criticism of the literature-based review 
method is that it is not methodological, has no clear-cut design, lacks transparency of the method and 
cannot be duplicated50. Additionally, the possibility of potential bias or selection bias is high51. Low 
retrievability of data is also raised as a disadvantage to the use of this type of research. The significant 
difference from other methodologies is that it does not directly deal with the object under study but 
indirectly accesses information from a variety of literature52. 
 
The table below provides an overview of the most common types of qualitative data collection 
approaches. It includes description, advantages, disadvantages and list of appropriate qualitative 
approaches. 
 
Table 4.2: Overview of the most common types of qualitative data collection46 
Method and Description Advantages Disadvantages Appropriate for these 
Approaches 
Structured Interviews: 
One-on-one interview using 
predetermined questions 
Easy to administer; quicker 
than other interviews 
Does not allow for follow up 
or variation; may lack depth 
Phenomenology; Grounded 
Theory; Ethnography; Case 
Study 
Unstructured Interviews: More in-depth; allows More time-consuming; less Narrative; Phenomenology; 
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No standard set of questions, 
often used to explore an 
idea; can use open-ended 
questions 
interviewer to follow up; 
less rigid; more open 
responses 
consistency in data collected Ethnography; Case Study 
Focus Groups: 
Group interview that uses 
group interactions to help 
formulate thoughts/ideas 
More time-effective; gather 
information from multiple 
people at once; provides 
social context  
Group dynamics can 
sometimes interfere with 
accuracy of the data; number 
of questions must be limited 
Grounded; Theory; 
Ethnography; 
Phenomenology 
Direct O bservation: 
Research gathers first  hand 
data on programs, processes 
or behaviors through direct 
observation and note-taking 
 
Can gain a holistic 
perspective by seeing full 
context; researcher can look 
for unexpected outcomes; 
occurs in the natural setting 
T ime-consuming; may effect 
behaviour of participants; 
perceptions of observer 
influence the data; may be 
intrusive 
Phenomenology; 
Ethnography; Case Study 
Participant O bservation: 
Researcher participates in 
activities rather than just 
observing; active 
participation/observation 
Active  participation 
provides more complete 
understanding and context; 
may be more natural/less 
intrusive 
May become too close to the 
topic or to the people 
involved in the study; may 
lose objectivity 
Ethnography; Case Study 
Written Documents: 
Researcher uses existing 
documents such as letters, 
memos, diaries, emails and 
so forth to study topic 
May provide factual 
information otherwise not 
attainable if writers are 
deceased: inexpensive 
May be subjective data from 
point of view of the writer; 
may be difficult to verify 
validity; may find 
conflicting information 
Narrative; Case Study 
Artifacts: 
Researcher study items 
made/used by different 
societies and cultures that 
provide evidence of the past  
Provides insight into how 
people lived, what they 
believed and valued, their 
knowledge and options 
May be difficult to interpret 
meaning and use; needs to 
be analyzed in appropriate 
context; often used in 
conjunction with other 
methods 
Narrative; Case Study 
 
 
4.1.2 Qualitative data analysis  
There are a variety of approaches to this process of analysis and interpretation. Some of the most 
commonly used approaches include46, 53: 
 
• Thematic analysis – details below in 4.1.2.1  
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• Content Analysis - used to analyze and interpret verbal data, or behavioral data. Content can be 
analyzed for descriptively or interpretatively. 
• Narrative Analysis - used to analyze text that may come from variety of sources including 
transcripts from interviews, diaries, field notes, surveys and other written forms. Narrative 
analysis often involves reformulating stories presented by people in different context and based 
on their different experiences. 
• Discourse Analysis - a method of analyzing naturally occurring spoken interactions and written 
text and is concerned with the social context in which the communication occurred. It focuses on 
how language is used in everyday life and looks at how people express themselves. 
• Grounded Theory - also called analytic induction. This is a method that attempts to develop 
causal explanations of a phenomenon from one or more cases being studied. Explanations are 
altered as additional cases are studied until the researcher arrives at a statement that fits all cases.  
• Conversation Analysis - examines the use of language by people as a type of action or skilled 
accomplishment. A key concept in this analysis is the principle of people taking turns in 
conversation. Meanings are usually shaped in the context of the exchange itself. 
 
Those are some of the most common methods. However, there are about fifteen methods including 
typology, taxonomy, analytic induction, logic analysis, quasi-statistics, event analysis, metaphorical 
analysis, domain analysis, hermeneutical analysis and semiotics54. 
 
4.1.2.1 Thematic analysis 
 
Thematic analysis is the process of identifying patterns or themes within qualitative data. Braun & 
Clarke (2006) suggest that it is the first qualitative method that should be learned as ‘….it provides core 
skills that will be useful for conducting many other kinds of analysis’ (p.78). A further advantage, 
particularly from the perspective of learning and teaching, is that it is a method rather than a 
methodology (Braun & Clarke 2006; Clarke & Braun, 2013). This means that, unlike many qualitative 
methodologies, it is not tied to a particular epistemological or theoretical perspective. This makes it a 
very flexible method, a considerable advantage given the diversity of work in learning and teaching53.  
The goal of a thematic analysis is to identify themes, i.e. patterns in the data that are important or 
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interesting and use these themes to address the research or say something about an issue. Braun & 
Clarke (2006) distinguish between two levels of themes: semantic and latent. Semantic themes 
‘…within the explicit or surface meanings of the data and the analyst is not looking for anything beyond 
what a participant has said or what has been written.’ (p.84). The analysis in this worked example 
identifies themes at the semantic level and is representative of much learning and teaching work. We 
hope you can see that analysis moves beyond describing what is said to focus on interpreting and 
explaining it. In contrast, the latent level looks beyond what has been said and ‘…starts to identify or 
examine the underlying ideas, assumptions, and conceptualizations – and ideologies - that are theorized 
as shaping or informing the semantic content of the data’ (p.84) 53. 
 
4.2 Research Approach 
This study employed the principles of explorative comprehensive literature-based review using a 
thematic qualitative approach. The method of data collection was documentation, collected and selected 
using document review and analysis. The methodology chosen was in keeping with the aims and 
objectives of the study to critically evaluate the proposed NDA biosimilar assessment guidelines with 
comparison of the proposed guidelines with those from chosen jurisdictions; and make 
recommendations for identified gaps, and also provide recommendations for best regulatory practices 
come across during the literature search. The chosen jurisdictions were the EU (EMA), South Africa 
(SAHPRA), USA (U.S.FDA) and WHO. 
The distinction between qualitative and quantitative research is a methodological issue. A 
comprehensive literature-based review is described as “an iterative, thematic approach to research 
where qualitative analysis is used to classify information contained in literature and come to a 
conclusion on the basis of qualitative description”48. Qualitative analysis has value in comparing 
literature, analyzing and proposing alternative strategies48. This was therefore the method of choice for 
the research. A review of the various qualitative research approaches to data analysis revealed that the 
thematic analysis method was most suited for the research project. For the project, themes obtained 
from the proposed NDA biosimilar guidelines were identified. Data was then organized into major 
themes and categories. Critical evaluation and assessment of the information under the various themes 
was performed using document analysis. Document analysis is defined as a ―systematic procedure for 
reviewing or evaluating documents51. It requires that data be examined and interpreted in order to elicit 
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meaning, gain understanding and develop empirical knowledge, by finding, selecting and apprais ing 
data contained in documents55.  
 
Document analysis also included comparison with guidelines from the chosen jurisdictions. A 
discussion of the results obtained and information gathered then followed. Experiences of practices in 
the various jurisdictions were evaluated some of which formed recommendations for inclusion in the 
proposed NDA guidelines. 
 
4.3Data collection 
The method of data collection was documentat ion, collected and selected using document review and 
analysis. Documentation used for the research was obtained by internet search, using the google search 
engine. Key words used for the search included: biosimilars, regulation of biosimilars, demonstration of 
biosimilarity, challenges in biosimilars regulation, future of biosimilars, opportunity for biosimilars, 
biosimilars and interchangeability, extrapolation of indications with respect to biosimilars and so on.  
The websites for the regulatory agencies in the chosen jurisdictions were also visited and available 
information on biosimilars reviewed. In order to keep up to date with recent developments for 
biosimilars, subscription was made to the Generics and Biosimilars Initiative (GaBi) and Biosimilar 
Development online journals. FDA’s Overview of Biosimilars online course19, was also taken with a 
certificate of completion awarded.  
 
To evaluate the NDA’s draft biosimilar assessment guidelines, data was organized into themes, and 
parameters for review and/or comparison were identified as follows. These were largely based on the 
structure in the proposed NDA biosimilar guidelines.  
 
• Structure/guideline organization  
• Table of contents  -  
• Terminology used  
• Definition (for biosimilars) as stated in guidelines 
• Introduction 
➢ The concept of Similar Biotherapeutic products 
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• General information 
➢ Considerations for the choice of Reference Biotherapeutic Product (RBP) 
• Other requirements 
➢ Manufacturer’s declaration 
• Submission requirements 
➢ Module 1: Administrative and Product Information 
➢ Module 2: Overview and summaries 
➢ Module 3: Quality 
❖ Qualitative and Quantitative Particulars 
❖ Manufacturing Process 
❖ Analytical Comparability 
❖ Analytical Procedure/technique/product Characterization 
➢ Module 4: Non Clinical Study 
(Special consideration, pharmacodynamics, toxicology) 
➢ Module 5: Clinical study 
(Pharmacokinetic (PK) Studies, pharmacodynamic (PD) Studies, clinical efficacy trials, 
Clinical safety and effectiveness, clinical Immunogenicity and pharmacovigilance) 
• Other guideline related documents: Summary Information for Similar Biotherapeutic Product 
(SIB) -  Appendix 2 
• Other principles  
➢ Policy on interchangeability 
➢ Possibility of extrapolation of efficacy and safety from  one therapeutic indication to 
another 
 
 
In keeping with the research objectives, the above criteria were used to critically review NDA’s 
proposed guideline. The various parameters especially the technical requirements (Module 3: Quality 
considerations, module 4: non-clinical requirements, and module 5: clinical requirements) , were 
compared with those in biosimilar guidelines from the chosen jurisdictions and also with related 
information on the official websites of these jurisdictions. In addition, a review of the entire guideline 
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was performed to identify inconsistencies. Review was not performed for certain sections. These were 
mentioned and justification for exclusion provided. 
 
The following guidelines obtained from the respective country/agency websites were reviewed in 
addition to the information on the websites. The scope of the proposed NDA guidelines is stated as 
“…These guidelines apply to well-established and well-characterized biotherapeutic products such as 
recombinant DNA-derived therapeutic proteins. Vaccines and plasma derived products and their 
recombinant analogues are excluded from the scope of these guidelines….” Therefore, only the 
biosimilar guidelines from the chosen jurisdictions that fall within this scope were selected.  
 
Table 4.3: Biosimilar Guidelines reviewed. 
Jurisdiction Guideline(s) name Current 
version date 
Reference  
EU Overarching biosimilar guidelines   
Guideline on similar biological 
medicinal products 
23 October 
2014 
https://www.ema.europa.eu/documents/s
cientific-guideline/guideline-similar-
biological-medicinal-products-
rev1_en.pdf 
Guideline on similar biological 
medicinal products containing 
biotechnology-derived proteins as 
active substance: non-clinical and 
clinical issues 
18 December 
2014 
https://www.ema.europa.eu/documents/s
cientific-guideline/guideline-similar-
biological-medicinal-products-
containing-biotechnology-derived-
proteins-active_en-2.pdf 
Guideline on similar biological 
medicinal products containing 
biotechnology-derived proteins as 
active substance: quality issues 
(revision 1) 
22 May 2014 https://www.ema.europa.eu/documents/s
cientific-guideline/guideline-similar-
biological-medicinal-products-
containing-biotechnology-derived-
proteins-active_en-0.pdf 
Biosimilars in the EU – Information 
guide for healthcare 
professionals** 
May 2017 https://www.ema.europa.eu/documents/le
aflet/biosimilars-eu-information-guide-
healthcare-professionals_en.pdf 
SA Biosimilar Medicines Quality, Non-
clinical and Clinical Requirements* 
August 2014 https://www.sahpra.org.za/documents/d2
59816c2.30_Biosimilars_Aug14_v3.pdf 
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Uganda Guidelines for Registration of 
Similar Biotherapeutic Products 
30 May 2018 Obtained from the Product 
Assessment and Registration 
directorate (NDA) – Refer to annexex 
1 and 2. 
USA Scientific Considerations in 
Demonstrating Biosimilarity to  a 
Reference Product 
April 2015 https://www.fda.gov/downloads/Drugs/G
uidanceComplianceRegulatoryInformati
on/Guidances/UCM291128.pdf 
Quality Considerations in 
Demonstrating Biosimilarity of a 
Therapeutic Protein Product to a 
Reference Product 
April 2015 https://www.fda.gov/downloads/Drugs/G
uidanceComplianceRegulatoryInformati
on/Guidances/UCM291134.pdf 
Clinical Pharmacology Data to 
Support a Demonstration of 
Biosimilarity to a Reference 
Product 
December 2016 https://www.fda.gov/downloads/Drugs/G
uidanceComplianceRegulatoryInformati
on/Guidances/UCM397017.pdf 
WHO Guidelines on evaluation of Similar 
Biotherapeutic Products (SBPs), 
Annex 2, Technical Report Series 
No. 977, 2009 
2009 http://www.who.int/biologicals/publicati
ons/trs/areas/biological_therapeutics/TR
S_977_Annex_2.pdf?ua=1 
WHO Guidelines on submission of 
documentation for the pilot 
procedure for prequalification of 
similar biotherapeutic products for 
rituximab and trastuzamab (full 
assessment) 
June 2018 http://www.who.int/medicines/regulation
/prequalification/02_GLs_Submission_Pi
lot_FullPathway_2018.pdf?ua=1 
*Annexure 1: Product Class Specific for Monoclonal Antibodies was not considered for this research.  
**Included for the glossary of terms contained therein, that is applicable to biosimilars. The EU overarching guidelines do not contain glossary of terms.  
 
4.4 Ethical considerations 
 
An official request to use NDA’s draft biosimilar assessment guideline for research purposes including  
request for a copy of the same, was sent by email to the NDA, Director of Product Assessment and 
Registration on 24 October 2018. Permission was granted on 26 October 2018, and a copy of the draft 
guidelines was provided. A copy of the permission letter and email correspondences is attached in 
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appendix II. A copy of the proposed NDA biosimilar guideline is attached in appendix III.  In the letter, 
a commitment was made to share research findings with NDA upon completion. The findings and 
recommendations were shared with NDA on 01 March 2019.  
 
 
Chapter Five: Results and Discussion 
 
5.1 Overall Structure/organization of guidelines   
This section was not subjected to comparison with other biosimilar guidelines from the chosen 
jurisdiction because it has no impact on the quality, safety and efficacy of biosimilars. Organization of 
guidelines is a country specific decision. Therefore, the proposed structure of the NDA guideline was 
reviewed. The guideline follows a CTD format, detailed in the proposed NDA guideline for registration 
of biotherapeutics which is also currently under preparation. The proposed biosimilar guideline makes 
reference to the proposed Biotherapeutics guideline for guidance on structure. The guidance is presented 
in a modular approach as follows, 
• Module 1: Administrative and Product Information 
• Module 2: Overview and summaries 
• Module 3: Quality 
• Module 4: Non Clinical study 
• Module 5: Clinical study 
According to information on the ICH website56, the agreement to assemble all the Quality, Safety and 
efficacy information in CTD format has revolutionized the regulatory review process, led to harmonized 
electronic submission that, in turn, enabled implementation of good review practices. For 
pharmaceutical manufacturers, it has eliminated the need to reformat the information for submission to 
the different regulatory agencies. It was initially designed to provide a common submission format 
between Europe, USA and Japan but it has now been accepted and implemented worldwide for 
regulatory submissions. According to the WHO guideline for the biosimilars pilot project57, many 
countries that import WHO prequalified medicinal products require the submission of a product dossier 
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in CTD format for registration of the products. The CTD format is therefore an acceptable form of 
submission of marketing authorization applications. 
 
5.2 Table of contents and glossary of Terms 
The table of contents was checked for accuracy and for inconsistencies. The proposed hyperlinks were 
working as intended and with the exception of a minor topographical error noted for part 2.2, no gaps 
were identified. In part 2.2, it was stated as Consideration For The Choice of Rbp instead of 
Consideration for the choice of RBP as stated in the body of the guidelines.  
 
The proposed glossary of terms was reviewed and checked for consistency with the purpose of 
identifying gaps. In addition, the terms and definitions were compared with those in guidelines from the 
chosen jurisdictions.  
 
For the consistency check, the proposed glossary terms were checked for inclusion in the body of the 
guideline. With the exception of the following, all terms defined were included in the body of the 
guideline. The following terms were defined in the glossary of terms but were not included in the 
guideline body: Genetic engineering and in-process control. It is recommended that the reference 
documents that were used to prepare the guidelines are revisited to consider either inclusion in the 
guidelines or exclusion, as considered appropriate.  
 
The terms and definitions were compared with those in guidelines from chosen jurisdictions to check 
whether they are comparable. Only the terms with concerns and recommendations for inclusion are 
discussed.  
 
5.2.1 Bioequivalence 
The proposed NDA definition is “Two proprietary preparations of a drug, when administered in the 
same dose and by the same route, will have the same bioavailability, duration of action and efficacy.” 
It was observed that bioequivalence was not defined in any of the guidelines reviewed from the chosen 
jurisdictions. However according to WHO’s Guidance for organizations performing in vivo 
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bioequivalence studies (Annex 9, Technical report series no. 996, 2016); “Two pharmaceutical products 
are bioequivalent if they are pharmaceutically equivalent or pharmaceutical alternatives, and their  
bioavailabilities, in terms of rate (Cmax and tmax) and extent of absorption (area under the curve), 
after administration of the same molar dose under the same conditions, are similar to such a degree 
that their effects can be expected to be essentially the same.”58 In the document Biosimilars in the EU-
Information guide for healthcare professionals59 bioequivalence is defined as “when two medicines 
release the same rate and to the same extent under similar conditions .” 
The proposed NDA definition is in line with the above definitions. However the term ‘bioavailability’ 
was not defined. Therefore, it is recommended that the definition be revised to include an explanation of 
the term. The WHO definition provides an extensive and complete definition which may be adopted.  
 
5.2.2 Biotherapeutics 
The proposed NDA definition is “therapeutic biological products, some of which are produced by 
recombinant DNA technology.” The definition makes reference to the terms biological products and 
recombinant DNA technology, which are also mentioned in the guideline but have not been defined.  
Of the guidelines reviewed, from the chosen jurisdictions, only the South African and U.S.FDA guides 
had a definition for biological products, as in Table 5.1.  
 
Table 5.1: Definition for biological products in South African (SAPHRA) and U.S.A (U.S.FDA) 
biosimilar guidelines 
South Africa Biological Medicine: 
All medicines that contain a living organism, or are derived from a living organism or 
biological processes are considered Biological Medicines. They include, but are not 
limited to the following:  
i. Plasma-derived and animal products, e.g. Clotting factors, Immunosera, 
Antivenoms  
ii. Vaccines 
iii. Biotechnology-derived medicines (rDNA products) e.g. rHu-
antihaemophilic factors, hormones, cytokines, enzymes, monoclonal 
antibodies, erythropoietins, nucleic acids;  
iv. Products developed for Human Gene therapy.  
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U.S. A Biological product: 
Virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component  or 
derivative, allergenic product, protein (except any chemically synthesized 
polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine 
(or any other trivalent organic arsenic compound), applicable to the prevention, 
treatment, or cure of a disease or condition of human beings. 
 
Both the above definitions are comprehensive. NDA may consider combining both definitions to come 
up with a comprehensive definition. The proposed definition for biological product based on the South 
African and U.S.A guidelines is “All products that contain a living organism, or are derived from a 
living organism or biological processes, applicable to the prevention, treatment, or cure of a disease or 
condition of human beings are considered biological products. These include viruses, therapeutic serum, 
toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any 
chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of 
arsphenamine (or any other trivalent organic arsenic compound).”  
 
For Recombinant DNA technology, the term was only defined in the EU information guide to 
healthcare professionals as “Technology that involves combining sequences of DNA that do not occur 
naturally, for example inserting a gene for producing a therapeutic protein.” This definition may be 
adopted by NDA.  
  
5.2.3 Comparability Exercise 
Comparability exercise is defined as “activities including study design, conduct of studies, and 
evaluation of data, that are designed to investigate whether the products are comparable (head to head 
comparison),” in the proposed NDA guideline. Head-to-head comparison is defined further on in the 
guideline. Of the guidelines reviewed, only the WHO and EU information guide to the health care 
providers have definitions for comparability exercise. 
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Table 5.2: Definition for comparability exercise in the EU and WHO biosimilar guidelines    
EU Head-to-head comparison of a biosimilar with its reference medicine to rule out any 
significant differences between them in terms of structure and function. This scientific 
principle is routinely used when a change is introduced to the manufacturing process of 
medicines made by biotechnology, to ensure that the change does not alter safety and 
efficacy. 
WHO 
Head-to-head comparison of a biotherapeutic product with a licensed originator product 
with the goal of establishing similarity in quality, safety and efficacy. Products should 
be compared in the same study using the same procedures. 
 
Comparison of the above definitions with the proposed NDA definition showed that the NDA definition 
could be improved and made more specific.  
The EU and WHO definitions are both comprehensive and take into account all aspects to be considered 
during a comparability exercise, that is to say; quality, safety and efficacy. It is therefore proposed that 
NDA adopts either of these definitions.   
 
5.2.4 ICH 
ICH is defined as follows in the proposed NDA guideline; 
“Means International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. ICH is a project that brings together the regulatory authorities of 
Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to 
discuss scientific and technical aspects of product registration. The purpose is to make 
recommendations on ways to achieve greater harmonization in the interpretation and application of 
technical guidelines and requirements for product registration in order to reduce or obviate the need to 
duplicate the testing carried out during the research and development of new medicines. For more 
information, see http://www.ich.org/.” 
 
According to the ICH website44, the membership of ICH has since grown and the list of observers 
increased. It is therefore proposed that NDA updates its definition in line with current information on 
the website. Alternatively, the definition may be deleted from the glossary of terms and instead included 
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in the list of abbreviations, with a link to the website. This will ensure that the ICH related information 
in the guideline is up to date. 
 
5.3 Terminology and Definition 
 
Table 5.3: Definition for Biosimilars/Similar Biotherapeutic Products (SBPs) in the proposed 
Uganda guideline and selected jurisdictions  
Country Terminology and Definition 
Uganda Similar Biotherapeutic Products (SBP)/Biosimilar 
The terms Similar biotherapeutic products and Biosimilars are used interchangeably 
throughout the guideline. 
 
A new biotherapeutic product claimed to be similar‟ to an already approved reference 
biotherapeutic product, which is marketed by an independent applicant, subject to all 
applicable data protection periods and/or intellectual property rights in the innovator 
product.  
The requirements for the registration of similar biotherapeutic product are based on the 
demonstration of similarity (i.e. no clinically meaningful difference between the similar 
biotherapeutic product and the reference biotherapeutic product) in terms of quality, safety 
and efficacy to an already registered, reference biological product. 
EU Similar biological medicinal products /Biosimilars  
(The terms Similar biological medicinal products and Biosimilars are used interchangeably 
throughout the three (3) overarching guidelines.)  
 
A biosimilar is a biological medicinal product that contains a version of the active 
substance of an already authorized original biological medicinal product (reference 
medicinal product) in EEA. 
South Africa Biosimilars 
A biosimilar is a biological medicine that is similar, but not necessarily identical, in terms 
of quality, safety and efficacy to an already registered reference biological medicine. It is 
synonymous with follow-on biologics and similar biotherapeutic products. 
U.S.A Biosimilar 
A biosimilar is a biological product that is highly similar to the reference product 
notwithstanding minor differences in clinically inactive components and that there are no 
clinically meaningful differences between the biological product and the reference product 
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in terms of safety, purity and potency of the product.  
WHO Similar biotherapeutic product (SBP) 
A biotherapeutic product that is similar in terms of quality, safety and efficacy to an 
already licensed reference biotherapeutic product.  
 
The different terminologies used for biosimilars in the chosen jurisdictions are stated in the table above. 
The terminology in the proposed NDA biosimilar guideline of Similar Biotherapeutic Products is the 
same as that used in the WHO biosimilar guidelines.  
The difference in terminologies for biosimilars is however a cause for concern. The WHO guideline 
states that a variety of terms have been coined to describe these products, such as biosimilar products, 
follow-on protein products and subsequent-entry biologics. According to the articles Terminology for 
biosimilars – a confusing minefield60, and Comparison of Global Regulatory Approvals for Biosimilar 
products61, the inconsistency in nomenclature used for biosimilars has led to confusion in referring to 
some products. According to the publications, this confusion is not just a potential concern for patient 
safety and efficacy, but can also lead to misconceptions which arise from misleading published reports 
on apparent problems with biosimilars.  
 
Several examples of misleading published reports have occurred, however, the most cited case is that of 
pure red cell aplasia in later stages of adrenal disease patient associated with stimulation of antibodies to 
administered erythropoietin (EPO) was seen in India. The patient had taken the EPO product Wepox 
(Wockhardt Limited, India) that was referred to as a ‘follow on’ product (biosimilar).However, there 
was no evidence that this product had been approved using the comparability approach required in the 
EU for biosimilarity and described in the WHO and other guidelines. This was in fact considered 
unlikely as the Indian regulatory process at the time did not include biosimilars (or follow-on products).  
The product Wepox is therefore not a biosimilar and should not have been described as such60,61. It was 
a clear misuse of terminology. It is therefore important that the terminologies are harmonized to avoid 
confusion. 
 
The definition for biosimilars across the five (5) jurisdictions is the same in principle with the exception 
of differences in wording. The major difference lays in the requirement for the reference biological 
products which will be discussed in detail under section 5.5.  
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5.4 Introduction 
5.4.1 The concept of Similar Biotherapeutic products  
 
Table 5.4: Concept for establishing biosimilarity in the proposed Uganda guidelines and selected 
jurisdictions  
Uganda Based on the comparability approach and when supported by state-of-the-art 
analytical systems, the comparability exercise at the quality level may allow 
reduction of the non-clinical and clinical data requirements compared to a full 
dossier. This in turn, depends on the clinical experience with the substance class and 
will be a case by case approach. 
 
The aim of the biosimilar approach is to demonstrate close similarity of the ‘similar 
biotherapeutic product’ in terms of quality, safety and efficacy to one chosen 
reference medicinal product, subsequently referring to the respective dossier. 
EU Stepwise approach recommended throughout the development programme: 
Starting with a comprehensive physicochemical and biological characterization 
(analytical studies and in vitro pharmaco-toxicological studies) 
↓* 
Extent and nature of the non-clinical in vivo studies and clinical studies depend on 
the level of evidence obtained in the previous step(s). 
 
In specific circumstances, a confirmatory clinical trial may not be necessary. This 
requires that similar efficacy and safety can clearly be deduced from the similarity of 
physicochemical characteristics, biological activity/potency, and PK and/or PD 
profiles of the biosimilar and the reference product. In addition, it requires that the 
impurity profile and the nature of excipients of the biosimilar itself do not give rise 
to concern. 
 
The ultimate goal of the biosimilar comparability exercise is to exclude any relevant 
differences between the biosimilar and the reference medicinal product. 
If the biosimilar comparability exercise indicates that there are relevant differences 
between the intended biosimilar and the reference medicinal product making it 
unlikely that biosimilarity will eventually be established, a stand-alone 
development to support a full Marketing Authorisation Application should be 
http://etd.uwc.ac.za/
54 
 
considered instead. 
South Africa Applicant should carry out a comprehensive physicochemical and biological (in 
vitro) characterization of the biosimilar API substance; each of these analyses must 
be conducted in a head-to-head comparison with the reference API substance.  
 
A lack of detectable, relevant differences between the biosimilar and the reference 
medicine is the basis for reducing non-clinical and clinical requirements for 
registration. 
U.S.A Stepwise approach is recommended. At each step, the sponsor should evaluate the 
extent to which there is residual uncertainty about the biosimilarity of the proposed 
product and identify next steps to try to address that uncertainty. 
Extensive structural and functional characterization of the proposed product and the 
reference product* 
↓ 
Consider the role of animal data in assessing toxicity and, in some cases, in 
providing additional support for demonstrating biosimilarity and in contributing to 
the immunogenicity assessment 
↓ 
Conduct comparative human PK and PD studies and compare the clinical 
immunogenicity of the two products in an appropriate study population 
↓ 
Comparative clinical study(ies)data If there is residual uncertainty about 
biosimilarity after conducting structural analyses, functional assays, animal testing, 
human PK and PD studies, and the clinical immunogenicity assessment, the sponsor 
should then consider what additional clinical data may be needed to adequately 
address that uncertainty 
 
* The more comprehensive and robust the comparative structural and functional characterization. The 
extent to which these studies are able to identify (qualitatively or quantitatively) differences in relevant 
product attributes between the proposed product and the reference product (including the drug substance, 
excipients, and impurities)—the more useful such characterization will be in determining what additional 
studies may be needed. For example, rigorous structural and functional comparisons that show minimal or 
no difference between the proposed product and the reference product will strengthen the scientific 
justification for a selective and targeted approach to animal and/or clinical testing to support a 
demonstration of biosimilarity. 
WHO Stepwise approach recommended: 
Characterization and evaluation of quality attributes of the product 
↓ 
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Nonclinical studies 
↓ 
Clinical studies 
Comprehensive characterization and comparison showing similarity at the quality 
level are the basis for possible data reduction in the nonclinical and clinical 
development. 
Any underlying differences should be fully explained and justified and may lead to 
additional data. 
*The symbol “↓” shows the stepwise approach in establishing biosimilarity. Requirements at a stage must be fulfilled before 
proceeding to the next.   
As stated in the table above , all guidelines in the five (5) jurisdictions recommend a stepwise approach 
for establishing biosimilarity. They require a comprehensive comparison of the quality attributes of the 
biosimilar and reference products. Fulfilment of this requirement determines the need and amount of 
additional studies required i.e. non-clinical and clinical studies. A risk-based approach is used to 
evaluate all data and information in support of the biosimilarity of the proposed product.  In all 
jurisdictions, applicants may be able to demonstrate biosimilarity even though there are formulation or 
minor structural differences, provided sufficient data and information demonstrating that the differences 
are not clinically meaningful is provided. However, the EU and U.S.A guidelines provide much more 
detailed information on the biosimilarity approach in comparison to the other jurisdictions. The types of 
studies at each step are specified. In addition, the clinically meaningful differences are defined. 
Statements from either the EU or U.S.A guidelines or a combination of the two (2) may be adopted in 
the proposed Uganda guidelines. This will provide further clarity to the applicants during product 
development and information to be submitted in the application.  
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5.5 General information 
Table 5.5: Considerations for choice of reference products(s) in the proposed Uganda guidelines 
and selected jurisdictions  
Jurisdiction/Country RBP should have 
marketing 
authorization in 
Jurisdiction or country 
Consideration for 
RBP(s) with no 
marketing 
authorization in 
jurisdiction or country 
Use of single RBP 
throughout the 
comparability 
programme 
Use of more than one 
RBPs during the 
comparability 
programme 
EU √ 
RBP must be authorized 
in EEA 
√ 
Possibility for applicant 
to compare the 
biosimilar in certain 
clinical studies and in 
vivo non-clinical studies 
(where needed) with a 
non-EEA authorized 
comparator authorized 
under similar scientific 
and regulatory standards 
as EMA (e.g. ICH 
countries)*. 
 
√ 
 
√ 
Combined use of EEA 
authorized reference 
product and non-EEA 
authorized comparator 
is acceptable for the 
development of the 
Quality Target 
Product Profile of 
biosimilar product 
South Africa √ 
RBP must be registered 
in South Africa** 
x √ 
 
x 
WHO N/A 
 
The RBP should have been marketed for a suitable 
duration and have a volume of marketed use such 
that the demonstration of similarity to it brings into 
relevance a substantial body of acceptable data 
regarding the safety and efficacy. 
 
The RBP should be licensed and widely marketed in 
N/A 
 
The same RBP should be used throughout the 
development of the SBP (i.e. throughout the 
comparative quality, nonclinical, and clinical 
studies) 
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another jurisdiction that has a well-established 
regulatory framework and principles, as well as 
considerable experience of evaluation of 
biotherapeutic products and post-marketing 
surveillance activities. 
 
The acceptance of an RBP for evaluation of an SBP 
in a particular country does not imply that the NRA 
of that country has approved the RBP for use. 
Uganda WHO recommendation fully adopted WHO recommendation fully adopted 
U.S.A. √ 
RBP should have been 
previously licensed by 
U.S FDA 
√ 
Possibility for applicant 
to use data derived from 
non-clinical or clinical 
comparing proposed 
biosimilar product with 
a non-U.S.-licensed 
comparator product* 
√ 
 
X 
√ - Yes 
X – No 
N/A – Not applicable. Recommendations included. 
 
*Applicant is required to provide adequate data or information to scientifically justify the relevance of these comparative data to an assessment of 
biosimilarity and establish an acceptable bridge to the U.S. -licensed RBP or EEA authorized RBP.  
 
**RBP must be sourced from a country that MCC (SAHPRA) aligns itself with.  
 
The EU, South Africa and U.S.A all require the RBP to have been licensed by their respective agencies. 
Both the EU and U.S.A provide for RBPs not licensed by their agencies, however, the alternative RBP 
should have been authorized under similar scientific and regulatory standards as EMA e.g. ICH 
countries or in the case of U.S.A, the applicant is required to provide adequate data or information to 
scientifically justify the relevance of the comparative data of the alternative RBP to an assessment of 
biosimilarity and establish an acceptable bridge to the U.S.-licensed RBP or EEA authorized RBP.  
 
Uganda adopted WHO’s recommendation for the RBP. However, there is  need for the requirements to 
be updated to suite Uganda. The proposed requirement is “The RBP should be registered in Uganda 
and/or by a stringent regulatory agency (SRA); and should have been marketed for a suitable duration 
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and have a volume of marketed use such that the demonstration of similarity to it brings into relevance a 
substantial body of acceptable data regarding the safety and efficacy.”  
The definition of an SRA has evolved over the years; however, the following WHO interim definition 
may be used62: 
• a member of the International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH), being the European Commission, the US Food and Drug 
Administration and the Ministry of Health, Labour and Welfare of Japan also represented by the 
Pharmaceuticals and Medical Devices Agency; or 
• an ICH observer, being the European Free Trade Association, as represented by Swissmedic, 
and Health Canada (as before 23 October 2015); or 
• a regulatory authority associated with an ICH member through a legally-binding, mutual 
recognition agreement, including Australia, Iceland, Liechtenstein and Norway (as before 23 
October 2015). 
 
All jurisdictions including Uganda require use of single RBP throughout the comparability programme. 
The EU however has provision for combined use of EEA authorized reference product and non-EEA 
authorized comparator for only the development of the Quality Target Product Profile of biosimilar 
product.  
 
Sourcing of the RBP is mentioned in the South African guideline. It is stated that the RBP should be 
sourced from a country that MCC (SAHPRA) aligns itself with. It is also expected that the RBP should 
be sourced from the EU or USA respectively in the case of EMA and U.S.FDA, or from countries that 
the two align themselves with as stated in the table. Sourcing of the RBP is however not mentioned in 
the proposed guidelines for Uganda. Provision for sourcing of RBP should be made in the guideline. 
The following information from the WHO website in reference to a bioequivalence study comparator 
product may provide useful guidance63: “To prove the origin of the comparator product, the applicant 
must include the following documents in the product dossier submitted for evaluation: 
 
• copy of the RBP labelling which should include: the name of the product; name and address of 
the manufacturer; batch number; and expiry date (clearly visible on the labelling) 
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• copy of the invoice from the distributor or company from which the RBP was purchased; the 
address of the distributor must be clearly visible on the invoice 
• documentation verifying the method of shipment and storage conditions of the RBP from the 
time of purchase to the time of study initiation 
• a statement ― by the company executive responsible for the application for registration 
certifying the authenticity of the above documents and that the RBP was purchased from the 
specified national market.” 
 
5.6 Other requirements  
 
This section was considered administrative and was not included in the research. However, the 
statement below under section 2.4.1 of the guideline was reviewed with a recommendation based on 
experiences from stringent regulators.  
5.6.1 Manufacturer’s declaration 
 “The applicants intending to develop SBPs should meet with regulators in their country of origin to 
present their product development plans and establish a schedule of milestones that will serve as 
standards for future discussions with the respective regulators.” 
Pre-submission meetings are very beneficial especially for complex medicinal products such as 
biosimilars. According to the Australian Government Department of Health Theraputic Goods 
Administration (TGA) website, the meetings help both the applicant and the agency to obtain a common 
understanding of the medicinal product, the supporting documentation needed to evaluate the 
application, any issues that need to be resolved before submitting applications; plan for submission and 
management of both timeframes and resources.  
 
Stringent regulators like; US FDA64, EMA65 and TGA66 have detailed guidance documents for pre-
submission meetings posted on their respective websites. The WHO Prequalification of medicines 
websites also has information and guidance notes on pre-submission meetings on its website . 
It is therefore recommended that NDA drafts a guidance document(s) for pre-submission meetings and 
preferably publish on the NDA website.  
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5.7 Submission requirements  
 
The proposed format for submission of biosimilar applications to NDA is the ICH CTD format, as in 
5.1. 
5.7.1 Module 1: Administrative and Product Information 
Module I of the CTD is administrative in nature and country or region specific. This will therefore be 
excluded from the comparison and research.  
5.7.2 Module 2: Overview and summaries  
Module 2 contains summaries of the quality (chemical, pharmaceutical, and biological) nonclinical and 
clinical information presented in modules 3, 4 and 5 of the CTD marketing authorization application. 
This will be excluded from the comparison and research.  
5.7.3 Module 3: Quality 
The quality aspects specific to biosimilars were compared. It is expected that much more information 
required for biologicals will be submitted as stipulated in the respective country or region guidelines for 
registration on biotherapeutic products.  
Table 5.5: Qualitative and Quantitative Particulars   
 Uganda EU South Africa U.S.A WHO 
Requirement: 
List of all components 
of the biosimilar and 
diluents if applicable 
√ √ √ √ √ 
Quantity per dose 
Name of active 
ingredient  
Special excipient 
characteristics e.g. 
water (purified, 
demineralized) 
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Table 5.6:  Manufacturing Process  
 Uganda EU South Africa U.S.A WHO 
The quality target product profile 
(QTPP) forms basis for 
development of biosimilar 
product and manufacturing 
process. 
Biosimilar is manufactured and 
controlled according to its own 
development taking into account 
state-of –the- art-information on 
manufacturing processes and 
consequences on product 
characteristics 
√ √ √ √ √ 
Demonstration of similarity:  
Differences between the chosen 
expression system of the 
proposed SBP and that of the 
RBP should be carefully 
considered and appropriately 
documented 
√ √ √ √ √ 
Characterization of the expression 
construct, including its genetic 
stability, should be demonstrated 
in accordance with principles 
recommended in ICH Q5 
Characterization tests, process 
controls, and specifications that 
will emerge from information 
gained during process 
development must be specific for 
the proposed SBP and the 
manufacturing process. 
Full Drug Master File (DMF), 
manufacturing process validation 
protocol and report should be 
submitted 
√ √ √ √ √ 
Product employing clearly 
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different approaches to 
manufacture from the reference 
product will not be eligible for 
registration as a SBP. 
 
Table 5.7: Analytical Comparability and Analytical Procedure/technique/product 
Characterization  
Summary of analytical 
considerations 
Extensive state-of-the-art characterization studies applied to the biosimilar and reference 
medicinal products in parallel 
Selected methods for comparability exercise should have ability to detect relevant variants with 
high sensitivity 
Characterizations to include determination of physicochemical properties, biological activity, 
immunochemical properties, purity, impurities, contaminants, and quantity. Product -related 
impurities, product-related substances, and process-related impurities should be identified, 
characterized as appropriate, quantified and compared to those of the RBP to the extent feasible 
and relevant, as part of an assessment of the potential impact on the safety, and potency of the 
product. 
Uganda √ 
EU √ 
South Africa √ 
U.S.A √ 
WHO √ 
 
The quality related principles required for establishing biosimilarity are the same across the selected 
jurisdictions including Uganda, although the EU and U.S.A guidelines provide in-depth information and 
explanations of the various principles. The proposed Uganda guideline makes reference to the EU and 
ICH guidelines for more detailed information.  
 
Quality principles include characterization of the reference product, analytical characterization of the 
biosimilar and, structural and functional comparison.68 The reference product is characterized to identify 
the product’s critical quality attributes (CQAs), characteristics that affect identity, purity, biological 
activity, and stability of a drug. 
For analytical characterization of the biosimilar, the biosimilar protein’s primary (ie, amino acid 
sequence) and higher-order structures (ie, secondary, tertiary, and quaternary) are analyzed. The 
enzymatic post-translational modifications (eg, glycosylation, phosphorylation), potential variations (eg, 
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oxidation), and intentional chemical modifications (eg, PEGylation sites) of the protein are additionally 
assessed. 
For structural and functional comparison, the structure of the biosimilar is closely compared with that of 
the reference product. The biosimilar then undergoes additional functional comparative testing to ensure 
that its biological activity, potency, and mechanism of action are highly similar to those of the reference 
biologic.  
 
5.7.4 Module 4: Non Clinical Study 
 
5.8: Non-clinical study considerations  
Summary of non-clinical study 
considerations 
Stepwise approach. Analytical studies and in vitro pharmaco-toxicological studies to be conducted first 
and decision is made as to what the extent of what, if any, in vivo work in animal studies will be 
required. 
 
Following approach recommended to be tailored to the concerned product on a case-by-case basis.  
 
Step 1: In vitro studies 
↓ 
Step 2: Determination of need for in vivo studies 
↓ 
Step 3: In vivo studies 
Step 1: In vitro studies 
Studies should include relevant assays on: 
-Binding to target(s)known to be involved in the pharmaco-toxicological effects and/or 
pharmacokinetics of the reference product  
 
-Signal transduction and functional activity /viability of cells known to be of relevance for the 
pharmaco-toxicological effects of the reference product. 
 
*Since  in vitro assays may often be more specific and sensitive to detect differences between the 
biosimilar and the reference product than studies in animals, these assays can be considered as 
paramount for the non-clinical biosimilar comparability exercise 
Step 2: Determination of need for in vivo studies 
Following factors are to be considered when the need for in vivo non-clinical studies is required (but not 
limited to): 
-Presence of potentially relevant quality attributes that have not been detected in the reference product 
(e.g. new post-translational modification structures).  
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-Presence of potentially relevant quantitative differences in quality attributes between the biosimilar and 
the reference product. 
-Relevant differences in formulation, e.g. use of excipients not widely used for biotechnology-derived 
proteins. 
*Although each of the factors mentioned above do not necessarily warrant in vivo testing, these issues 
should be considered together to assess the level of concern and whether there is a need for in vivo 
testing. 
Step 3: In vivo studies 
-PK and PD of the biosimilar and the reference product should be quantitatively compared (if model 
allows) 
 
-Although immunogenicity assessment in animals is generally not predictive for immunogenicity in 
humans, it  may be needed for interpretation of in vivo studies in animals. Therefore, blood samples 
should be taken and stored for future evaluations of pharmacokinetic/toxicokinetic data if then needed.   
 
-Studies regarding safety pharmacology, reproduction toxicology, and carcinogenicity are not required 
for non-clinical testing of biosimilars.  
 
- Studies on local tolerance are usually not required. However, if excipients are introduced for which 
there is no or lit t le experience with the intended clinical route of administration, local tolerance may 
need to be evaluated. If other in vivo studies are performed, evaluation of local tolerance may be part of 
the design of that study instead of the performance of separate local tolerance studies. 
Uganda √ 
EU √ 
South Africa √ 
U.S.A √ 
WHO √ 
*The symbol “↓” shows the stepwise approach in establishing biosimilarity. Requirements at a stage must be fulfilled before 
proceeding to the next.   
The non-clinical, also known as pre- clinical principles required for establishing biosimilarity are the 
same across the selected jurisdictions including Uganda, although as mentioned for the quality attributes, 
the EU and U.S.A guidelines provide in-depth information and explanation of the various principles. 
The Ugandan guideline provides reference to the EU and ICH guidelines for more detailed information.  
 
Preclinical studies involve comparison of in vivo pharmacology (PK and PD), toxicology, and immune 
response. A comparison of nonclinical PK and PD may be useful in reducing residual uncertainty 
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regarding similarity, and such a study may be conducted as a comparative single-dose study or 
incorporated into a single preclinical toxicity study if appropriate. Immunogenicity may also be 
evaluated in animal studies; results may aid in detection of differences between the proposed biosimilar 
and reference product as opposed to predicting clinical similarity in immunogenicity69. 
 
5.7.5 Module 5: Clinical study 
 
Table 5.9: Clinical study considerations  
Description of clinical study 
considerations 
It  is recommended to generate the clinical data required for the biosimilar comparability exercise with 
the biosimilar product derived from the commercial manufacturing process and therefore representing 
the quality profile of the batches to become commercialized. (Any deviation to be justified and 
supported by adequate bridging data). 
 
The clinical biosimilar comparability exercise is a stepwise approach, as follows: 
 
PK (and PD, if feasible) Clinical efficacy and safety trial(s), (or, in certain cases, confirmatory PK/PD 
studies for demonstrating clinical biosimilar comparability) 
Summary of clinical studies to be performed: 
a) PK* 
b) PD (if feasible)* 
c) Clinical efficacy of the biosimilar and reference product (study designs and efficacy endpoints 
specified). 
d) Clinical safety (comparative safety data), immunogenicity testing  (in a comparative manner to 
the reference product) 
* In certain cases, comparative PK/PD studies may be sufficient to demonstrate clinical comparability of 
the biosimilar and the reference medicinal product, provided that the following conditions are met:  
• The selected PD marker/biomarker is an accepted surrogate marker  and can be related to patient 
outcome to the extent that demonstration of similar effect on the PD marker will ensure a similar effect 
on the clinical outcome.  
• There may be PD-markers that are not established surrogates for efficacy but are relevant fo r the 
pharmacological action of the active substance and a clear dose-response or a concentration-response 
relationship has been demonstrated. In this case, a single or multiple dose-exposure-response study at 
two or more dose levels may be sufficient to waive a clinical efficacy study. 
Uganda √ 
EU √ 
South Africa √ 
U.S.A √ 
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WHO √ 
 
The clinical principles required for establishing biosimilarity are the same across the selected 
jurisdictions including Uganda. As mentioned for the quality, and non-clinical attributes, the EU and  
 
 
U.S.A guidelines provide in-depth information and explanation of the various principles. The Ugandan 
guideline provides reference to the EU and ICH guidelines for more detailed information. 
The goal of the clinical development program for a biosimilar is to demonstrate the absence of any 
clinically meaningful difference relative to the reference molecule. The extent of the clinical program 
depends on the degree of similarity demonstrated in preclinical testing, including structural, functional, 
and animal studies. Clinical studies include human pharmacology studies (PK and PD), efficacy and 
safety, immunogenicity and extrapolation.69  
 
5.7.5.1 Pharmacovigilance 
Table 5.10:  Pharmacovigilance requirement  
 Uganda EU South Africa U.S.A WHO 
Requirement for close 
monitoring of the clinical 
safety of a biosimilar in all 
approved indications and a 
continued benefit -risk 
assessment in the post -
marketing phase 
√ √ √ √ √ 
 
All selected jurisdictions including Uganda recommend a comprehensive pharmacovigilance plan to be 
submitted as part of the marketing authorization application, taking into account immunogenicity risks 
identified during product development as well as any anticipated future risks (RMP).   
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5.7.5.1.1 Risk Management Plan (RMP) 
Table 5.11: Requirement for RMP  
 Uganda EU South Africa U.S.A WHO 
Requirement for RMP at 
the time of submission of 
the marketing 
authorization application 
√ 
 
To be submitted 
along with a 
Periodic Benefit -
Risk Evaluation 
Report (PBRER), 
in accordance with 
principles of 
pharmacovigilance 
planning found in 
relevant guidelines 
such as ICH E2E.  
√ 
 
Marketing 
authorization 
applications 
should include a 
description of the 
pharmacovigilance 
system and RMP 
in accordance with 
EU legislation and 
pharmacovigilance 
guidelines. 
√ 
 
Applicant should 
present a 
pharmacovigilance 
plan/risk 
management plan 
with the registration 
application, 
according to the 
SAHPRA 
guidelines. RMP 
should be in place 
(or planned) for the 
biosimilar at the 
time of application. 
 
It  may be necessary 
to include South 
African and special 
population groups 
in RMP activities.  
X 
 
Unlike the 
mandatory RMP in 
the EU, South 
Africa, WHO and 
Uganda; the U.S 
has a Risk 
Evaluation and 
Mitigation 
Strategies (REMS) 
program.* REMS 
programs are 
created by the 
sponsor at the 
request of the FDA, 
either pre-or post-
approval76. 
√ 
 
Manufacturer is 
required to submit 
a safety 
specification and 
pharmacovigilance 
plan (RMP) at the 
time of 
submission of the 
marketing 
authorization 
application, in 
accordance with 
principles of 
pharmacovigilance 
planning found in 
relevant guidelines 
such as ICH E2E. 
√ - Yes/available 
X – No/not available 
 
*According to information on the U.S. FDA website, a Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the U.S. Food and 
Drug Administration (FDA) can require for cert ain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. 
REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication. While all m edications have labeling that 
informs health care stakeholders about medication risks, only a few medications require a REMS.  
REMS are not designed to mitigate all the adverse events of a medication, these are communicated to health care providers in the medication’s prescribing 
information. Rather, REMS focus on preventing, monitoring and/or managing a specific serious risk by informing, educating and /or reinforcing actions to 
reduce the frequency and/or severity of the event.   
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According to the WHO guideline for the biosimilars pilot project57, a risk management plan is a detailed 
description of the activities that continuously ensure patients’ safety and their benefit from a medicinal 
ingredient. A risk management plan includes: 
• safety specifications, which summarize the known and potential safety issues and missing 
information about the rDNA-derived biotherapeutic;  
• a pharmacovigilance plan to further evaluate important known or potential safety concerns and 
to provide post-marketing data where relevant information is missing;  
• a risk minimization plan, which provides proposals on how to minimize any identified or 
potential safety risk.  
With the exception of the U.S.A with a non-mandatory REMS program at the time of submission of 
marketing authorization application, all other jurisdictions including Uganda require submission of a 
RMP at the time of submission of the marketing authorization application.  
Uganda’s proposed guideline has an additional requirement for a PBRER at the time of submission of 
the marketing authorization application. However, according to the ICH guideline E2C70, the main 
objective of a PBRER is to present a comprehensive, concise, and critical analysis of new or emerging 
information on the risks of the medicinal product, and on its benefit in approved indications, to enable 
an appraisal of the product’s overall benefit-risk profile. It is a post-marketing approval requirement and 
not a pre-marketing requirement as proposed in the guideline. It is recommended that this requirement is 
removed as pre-market requirement and included as a post-market requirement in addition to post-
marketing safety commitments such as targeted questionnaires, phase IV studies, registries, and 
specialized follow-up for long-term use71.  
It is also recommended that a reference or link to the existing Ugandan pharmacovigilance requirements 
is included, such as the Guidelines on submitting periodic safety update report and other reports that 
may be relevant to determine the safety, eff icacy and quality of a drug, April 2018, available on the 
NDA website: www.nda.or.ug. 
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5.8 Other guideline related documents: Summary Information for Similar Biotherapeutic Product 
(Appendix 2) 
 
It is stated under section 2.1 of the proposed guideline that a template of the Summary Information for 
Similar Biotherapeutic Product (SIB) is attached as appendix 2 of the guideline. General information of 
the components SIB template is intended to be filled out by the MAH while NDA will fill out the 
components which are general for the product summary including the status of the registered product. 
The SIB will be filled out with the dossier of first authorization. For any amendment, SIB will be 
updated. The purpose of the SIB was not mentioned. Although the title suggests that SIB contains 
summary information of the biosimilar, this is not clearly stated.  
WHO published a Quality Information Summary template (QIS) for medicines on its website72. It is 
stated that the QIS provides an accurate record of technical data in the product dossier (PD) at the time 
of prequalification and thereafter serves as an official reference document during GMP inspections, 
variation assessments and requalification assessments as performed by WHO. It represents the final, 
agreed upon key information from the PD review73. This information is included in the WHO QIS 
template covering forward and may serve as a guide for drafting the purpose of the proposed SIB.   
 
However, Appendix 2 of the proposed guideline contains a template of the Public Assessment Summary 
Information for Similar Biotherapeutic Product and not a SIB template as stated. The format and content 
of the Public Assessment Summary Information for Similar Biotherapeutic Product appended is the 
same as that of the Public Assessment Summary Information for Biosimilars (PASIB) published by the 
IPRP Biosimilar Working Group (IPRP-BWG) 37. According to the IPRP website, the PASIB template 
is intended to assist National Regulatory Authorities (NRAs) in making available a summary of the 
assessment (review) of biosimilar applications in their jurisdiction / country in a common language , for 
example, in English. For NRAs who already publish assessment reports following the review of 
medicinal product applications in their country, these are often in the local language and as a result are 
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not easily accessible to the wider (global) community. The PASIB is intended to increase transparency 
and to facilitate the transition from a local assessment report to one prepared in the English language. 
The PASIB includes key information and summarized details of the biosimilar review. The template 
and its use were designed to reduce local translation effort by the NRA to a minimum and should be  
completed in accordance with local requirements, however, if found to be helpful the applicant / 
sponsor for the biosimilar can populate data elements of the document in English, as part of the 
process37. Therefore, in order to avoid confusion, the PASIB should be removed and a SIB attached as 
appendix 2. In drafting a SIB, the PASIB template may provide useful information for inclusion in the 
SIB as applicable to the Ugandan situation. For example, the PASIB requires inclusion of information 
on interchangeability and extrapolation of indications, areas for which the proposed biosimilar guideline 
is not clear.  
 
5.9 Other principles  
5.9.1 Policy on interchangeability 
Table 5.12: Statements on interchangeability   
Uganda EU South Africa U.S.A WHO 
Interchangeability, 
substitution and 
switching are 
defined in the 
proposed guideline 
but are not 
addressed anywhere 
else in the 
guideline. NDA’s 
position on 
interchangeability is 
unknown.  
EMA does not regulate 
interchangeability, switching and 
substitution of a reference 
medicine by its biosimilar.  
These fall within the remit of EU 
Member States 
Biosimilars are not 
considered to be 
interchangeable with the 
reference medicine or other 
medicines of the same class. 
 
Substitution in terms of 
Section 22F (Generic 
substitution) of Act 101 of 
1965 (i.e. the practice by 
with a different product to 
that specified on the 
prescription is dispensed to 
the patient without the prior 
informed consent of the 
treating physician) does not 
apply to Biosimilars. 
In U.S.A, a biosimilar may 
be substituted for the 
reference product without 
intervention of the health 
care provider who 
prescribed the reference 
product.  
 
However, general 
scientific issues relating to 
the demonstration on 
interchangeability are not 
included in the reviewed 
guidelines are addressed 
separately on the U.S. 
FDA website.  
Not applicable. 
 
It  is stated that important 
issues associated with the 
use of SBPs including 
interchangeability and 
substitution of RBP with 
SBP, need to be defined 
by NRAs and are 
therefore not elaborated in 
the guideline. 
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Of all the jurisdictions reviewed, only USA has a policy on interchangeability with respect to 
biosimilars and reference products. According to information on the page Biosimilar and 
Interchangeable Products on the U.S FDA website74, an interchangeable product is a biosimilar 
product that meets additional requirements outlined by the Biologics Price Competition and Innovation 
Act. As part of fulfilling these additional requirements, information is needed to show that an 
interchangeable product is expected to produce the same clinical result as the reference product in any 
given patient. Also, for products administered to a patient more than once, the risk in terms of safety 
and reduced efficacy of switching back and forth between an interchangeable product and a reference 
product has to be evaluated. An interchangeable product may be substituted for the reference product 
without the involvement of the prescriber. FDA’s high standards for approval are expected to assure 
health care providers that they can be confident in the safety and effectiveness of an interchangeable 
product, just as they would be for an FDA-approved reference product74. 
 
The proposed biosimilar guideline does not mention NDA’s position on interchangeability and/or 
substitution. This position needs to be clearly stated in the guideline. A clear definitive policy on 
interchangeability will ensure better outcomes for patients without placing inordinate burden on health 
care professionals. 
 
5.9.2 Possibility of extrapolation of efficacy and safety from one therapeutic indication to another 
 
Table 5.13: Statements on extrapolation of efficacy and safety from one indication to another   
Uganda EU South Africa U.S.A WHO 
No clear statement on 
extrapolation of biosimilar 
from one indication to 
another. Reference made to 
WHO guideline.  
If biosimilarity has been 
demonstrated in one 
indication, extrapolation to 
other indications of the 
reference product could be 
acceptable with appropriate 
justification. 
 
Extrapolation should be 
considered in the light of the 
Where the clinical 
effects of the medicine 
have been shown to be 
related to the same mode 
of actions and the safety 
and efficacy of the 
biosimilar medicine and 
the reference product 
have been demonstrated 
for a particular clinical 
If the proposed product 
meets the statutory 
requirements for licensure 
as a biosimilar product 
under section 351(k) of the 
PHS Act based on, among 
other things, data derived 
from a clinical study or 
studies sufficient to 
demonstrate safety, purity, 
If similarity between the 
SBP and the RBP has 
been convincingly 
demonstrated, and if the 
manufacturer can provide 
scientific justification for 
such extrapolation, the 
SBP may be approved for 
use in other clinical 
indications for which the 
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totality of data, i.e. quality, 
non-clinical and clinical data. 
 
Extrapolation of 
immunogenicity from the 
studied indication /route of 
administration to other uses of 
the reference product should 
be justified. 
indication, it  may be 
possible to extrapolate 
these data to other 
indications of the 
reference product that 
have not been 
independently and 
specifically studied for 
the biosimilar medicine 
in clinical trials. 
 
The applicant should 
provide convincing 
motivation and in detail 
discuss the scientific 
basis and the risk/benefit  
for the proposed 
extrapolated clinical 
indications. 
 
Safety and 
immunogenicity of the 
biosimilar product must 
be sufficiently 
characterized. 
and potency in an 
appropriate condition of 
use, the applicant may seek 
licensure of the proposed 
product for one or more 
additional conditions of 
use for which the reference 
product is licensed. 
 
However, the applicant 
would need to provide 
sufficient scientific 
justification for 
extrapolating clinical data 
to support a determination 
of biosimilarity for each 
condition of use for which 
licensure is sought. 
RBP is used but which 
have not directly been 
tested in clinical trials. 
 
Any significant 
differences between the 
SBP and the chosen RBP 
detected during the 
comparability exercise 
would indicate that the 
products are not similar 
and that more extensive 
nonclinical and clinical 
data may be required to 
support the application for 
licensing. 
 
With the exception of Uganda, guidelines from all the jurisdictions provide for extrapolation of clinical 
data across indications with sufficient scientific justification for extrapolating clinical data to support 
determination of biosimilarity for each condition of use for which marketing authorization is sought. 
The U.S.A guidelines on Scientif ic considerations in Demonstrating Biosimilarity to a Reference 
Product, give examples of such scientific justification.   
 
The proposed NDA biosimilar guideline lacks a clear statement on extrapolation of biosimilar from one 
indication to another. It is instead stated that the WHO guideline should be consulted for further 
guidance on extrapolation. It is however considered important that information on extrapolation is 
provided in the guideline including examples of scientific justification that may be provided as in the 
U.S.FDA guideline. For further information, the reflection paper prepared by the IPRF Biosimilars 
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Working Group (BWG) is a useful document for understanding the current thinking of various 
regulatory authorities of different regions with respect to the extrapolation of indications from reference 
product to the biosimilar during the development of these products75. 
 
 
Chapter Six: Conclusion and recommendations 
 
In general, the findings reveal that the proposed Uganda biosimilar guidelines are comparable with 
those from the chosen jurisdictions, i.e. the EU, South Africa, U.S.A and WHO, with respect to the 
technical principles required in establishing biosimilarity; quality, non-clinical and clinical requirements. 
All the guidelines from the five (5) jurisdictions recommend a stepwise approach in establishing 
biosimilarity. They require a comprehensive comparison of the quality attributes of the biosimilar and 
reference products. Fulfilment of this requirement then determines the need and amount of additional 
studies required i.e. non-clinical and clinical studies. A risk-based approach is used to evaluate all data 
and information in support of the biosimilarity of the proposed product.  It was however noted that 
specifically the EU and U.S.A guidelines provide detailed information on the biosimilarity approach in 
comparison to the other jurisdictions. The types of studies at each step are specified in detail. In addition, 
the clinically meaningful differences that would lead to rejection of biosimilar applications are defined.  
In addition to the technical assessment requirements, all guidelines from selected jurisdictions and the 
proposed Uganda guideline recommend a comprehensive pharmacovigilance plan to be submitted as 
part of the marketing authorization application. 
 
The selected jurisdictions have clearly stated positions on reference product requirements including 
origin and sourcing; interchangeability and/or substitution; and on the possibility of extrapolation of 
efficacy and safety from one therapeutic indication to another. However, Uganda’s position is not stated 
in the guideline. This should be included in the guideline.  
 
The general guideline review also revealed a number of inconsistencies which were highlighted and 
recommendations for revision and/or improvement made. A comprehensive list of recommendations to 
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NDA, Uganda, for inclusion in the proposed guidelines is included as Annexure I.  A copy of the same 
was shared with NDA by email on 01 March 2019.  
 
In conclusion, the proposed biosimilar assessment guideline with revisions will go a long way in 
ensuring that Uganda’s NDA effectively regulates these products to ensure that safe, efficacious and 
good quality biosimilars are available on the market.  They will also serve as a starting point in 
increasing public and health care provider confidence in these products. The proposed assessment 
guidelines are comparable with those from the selected jurisdictions with respect to the key technical 
assessment principles. These should be finalized with recommended revisions and made available, for 
example, on the NDA website.  
In future, it would be of value to review the process of developing scientific guidelines at NDA. 
Guidelines are key documents with a huge potential to prevent access to quality medicines if not 
developed according to international standards. Also, the available resources and capacity, including 
competence, for biosimilars regulation in Uganda can be assessed to identify gaps and make 
recommendations aimed at ensuring a strong and effective biosimilars regulatory system.   
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Appendix I: Recommendation 
 
1.0 Recommendations: Guideline update  
Guideline section Finding Recommendation 
Table of contents “2.2 Considerations For The Choice Of Rbp” 
 
Proposed revision: 
 
2.2 Consideration for the choice of RBP 
 
Glossary of Terms (0.3) Terms Genetic engineering and in-process 
control are defined but not included in 
guideline body 
 
Review documents used for guideline preparation and 
consider inclusion or exclusion, as appropriate 
Bioequivalence: 
 
“Two proprietary preparations of a drug, when 
administered in the same dose and by the 
same route, will have the same bioavailability, 
duration of action and efficacy” 
 
The term bioavailability was not defined 
To consider adoption of the WHO definition as follows: 
 
“Two pharmaceutical products are bioequivalent if they are 
pharmaceutically equivalent or pharmaceutical alternatives, 
and their bioavailabilities, in terms of rate (Cmax and tmax) 
and extent of absorption (area under the curve), after 
administration of the same molar dose under the same 
conditions, are similar to such a degree that their effects can 
be expected to be essentially the same.” 
Biotherapeutics: 
 
“Therapeutic biological products, some of 
which are produced by recombinant DNA 
technology” 
 
The terms biological products and 
recombinant DNA technology are used and 
also mentioned in the guideline but were not 
defined 
Biological products/medicines: 
 
South Africa  
All medicines that contain a living organism, or are derived 
from a living organism or biological processes are considered 
Biological Medicines. They include, but are not limited to the 
following:  
v. Plasma-derived and animal products, e.g. Clotting 
factors, Immunosera, Antivenoms  
vi. Vaccines 
vii. Biotechnology-derived medicines (rDNA products) 
e.g. rHu-antihaemophilic factors, hormones, 
cytokines, enzymes, monoclonal antibodies, 
erythropoietins, nucleic acids;  
viii. Products developed for Human Gene therapy.  
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U.S.A 
Virus, therapeutic serum, toxin, antitoxin, vaccine, blood, 
blood component or derivative, allergenic product, protein 
(except any chemically synthesized polypeptide), or analogous 
product, or arsphenamine or derivative of arsphenamine (or 
any other trivalent organic arsenic compound), applicable to 
the prevention, treatment, or cure of a disease or condition of 
human beings. 
 
Proposed: 
Consider adopting any of the above or a combination of the 
two, e.g., 
 
“All products that contain a living organism, or are derived 
from a living organism or biological processes, applicable to 
the prevention, treatment, or cure of a disease or condition of 
human beings are considered biological products. These 
include viruses, therapeutic serum, toxin, antitoxin, vaccine, 
blood, blood component or derivative, allergenic product, 
protein (except any chemically synthesized polypeptide), or 
analogous product, or arsphenamine or derivative of 
arsphenamine (or any other trivalent organic arsenic 
compound)” 
 
Recombinant DNA technology 
Consider adoption of the EU definition; 
 
“Technology that involves combining sequences of DNA that 
do not occur naturally, for example inserting a gene for 
producing a therapeutic protein” 
Comparability Exercise: 
 
“Activities including study design, conduct of 
studies, and evaluation of data, that are 
EU and WHO definitions are more comprehensive. Either of 
these may be adopted. 
 
EU: 
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designed to investigate whether the products 
are comparable (head to head comparison)” 
Head-to-head comparison of a biosimilar with its reference 
medicine to rule out any significant differences between them 
in terms of structure and function. This scientific principle is 
routinely used when a change is introduced to the 
manufacturing process of medicines made by biotechnology, 
to ensure that the change does not alter safety and efficacy. 
 
WHO: 
Head-to-head comparison of a biotherapeutic product with a 
licensed originator product with the goal of establishing 
similarity in quality, safety and efficacy. Products should be 
compared in the same study using the same procedures. 
ICH: 
 
“Means International Conference on 
Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human 
Use. ICH is a project that brings together the 
regulatory authorities of Europe, Japan and the 
United States and experts from the 
pharmaceutical industry in the three regions to 
discuss scientific and technical aspects of 
product registration. The purpose is to make 
recommendations on ways to achieve greater 
harmonization in the interpretation and 
application of technical guidelines and 
requirements for product registration in order 
to reduce or obviate the need to duplicate the 
testing carried out during the research and 
development of new medicines. For more 
information, see http://www.ich.org/.” 
 
According to the ICH website, the ICH membership has 
grown and the list of observers increased: 
https://www.ich.org/about/members-observers.html 
 
Proposed: 
NDA to update definition in line with current information on 
the ICH website. Alternatively, the definition may be deleted 
from the glossary of terms and instead included in the list of 
abbreviations, with a link to the website. This will ensure that 
the ICH related information in the guideline is up to date. 
The Concept of Similar 
Biotherapeutic Products 
(1.1) 
 Statements in the EU and U.S.A guidelines provide detailed 
information on the biosimilarity approach, and may be 
adopted. The types of studies are specified at each step, and 
differences considered to be clinically meaningful are defined.   
Considerations for the WHO text was fully adopted. However this Proposed: 
http://etd.uwc.ac.za/
84 
 
choice of RBP (2.2) was not adapted to the Ugandan 
situation/domesticated 
“The RBP should be registered in Uganda or by a stringent 
regulatory agency (SRA) or a regulatory agency that NDA 
aligns itself with; and should have been marketed for a 
suitable duration and have a volume of marketed use such that 
the demonstration of similarity to it brings into relevance a 
substantial body of acceptable data regarding the safety and 
efficacy.” 
The definition of an SRA has evolved over the years; however 
the following WHO interim definition may be used: 
• a member of the International Council for 
Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH), being the 
European Commission, the US Food and Drug 
Administration and the Ministry of Health, Labour 
and Welfare of Japan also represented by the 
Pharmaceuticals and Medical Devices Agency; or 
• an ICH observer, being the European Free Trade 
Association, as represented by Swissmedic, and 
Health Canada (as before 23 October 2015); or 
• a regulatory authority associated with an ICH 
member through a legally-binding, mutual 
recognition agreement, including Australia, Iceland, 
Liechtenstein and Norway (as before 23 October 
2015). 
 
Information on sourcing of the RBP should be included the 
guideline. The following obtained from the WHO PQP 
website, for comparator products used in bioequivalence study 
may be used for guidance: 
“To prove the origin of the comparator product, the applicant 
must include the following documents in the product dossier 
submitted for evaluation; 
• copy of the RBP labelling which should include: the 
name of the product; name and address of the 
manufacturer; batch number; and expiry date (clearly 
visible on the labelling) 
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• copy of the invoice from the distributor or company 
from which the RBP was purchased; the address of 
the distributor must be clearly visible on the invoice 
• documentation verifying the method of shipment and 
storage conditions of the RBP from the time of 
purchase to the time of study initiation 
• a statement ― by the company executive responsible 
for the application for registration certifying the 
authenticity of the above documents and that the 
RBP was purchased from the specified national 
market.” 
Manufacturer’s declaration 
(2.4.1) 
It was stated that….    “applicants intending to 
develop SBPs should meet with regulators in 
their country of origin to present their product 
development plans and establish a schedule of 
milestones that will serve as standards for 
future discussions with the respective 
regulators”  
 
Proposed: 
To draft a guidance document(s) for pre-submission meetings 
and preferably publish on the NDA website. 
The following  documents/information may be used for 
guidance: 
• U.S.FDA 
 (Formal Meetings Between the FDA and Sponsors or 
Applicants of Bs UFA Products; Guidance for Industry; Draft 
Guidance, June 2018,)  
• EMA 
Pre-authorisation guidance; EMA 
• WHO 
Pre-submission meetings; WHO Prequalification 
• TGA 
Pre-submission meetings with TGA 
Quality (module 3), Non-
clinical (module 4) and 
Clinical considerations 
(module 5) 
 Develop a system of regularly checking references stated to 
ensure that they are current. Information on EMA, U.S. FDA, 
ICH and WHO websites is regularly updated including 
guidelines. 
 
NDA should also consider providing detailed information as is 
the case with the EU and U.S.A. This may be provided as 
appendices to the main guideline. This will not only provide 
readily accessible information to the applicants during product 
development and clarity on information to be submitted in the 
application, but will also provide information for capacity 
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building of Uganda’s biosimilar assessors. 
 
Pharmacovigilance (5.6) 
/Risk Management Plan 
(RMP) 
Proposed guideline has an additional 
requirement for a PBRER at the time of 
submission of the marketing authorization 
application.  
 
However, according to the ICH guideline 
E2C, the main objective of a PBRER is to 
present a comprehensive, concise, and critical 
analysis of new or emerging information on 
the risks of the medicinal product, and on its 
benefit in approved indications, to enable an 
appraisal of the product’s overall benefit-risk 
profile.  
It is a post-marketing approval requirement 
and not a pre-marketing requirement as 
proposed in the guideline. 
It is recommended that this requirement is removed as pre-
market requirement and included as a post-market requirement 
in addition to post-marketing safety commitments such as 
targeted questionnaires, phase IV studies, registries, and 
specialized follow-up for long-term use, if considered feasible 
(taking into consideration available resources) 
 It is also recommended that a reference or link to the existing 
Uganda pharmacovigilance requirements is included, such as 
the Guidelines on submitting periodic safety update report 
and other reports that may be relevant to determine the safety, 
efficacy and quality of a drug, April 2018, available on the 
NDA website: www.nda.or.ug. 
 
Appendix 2: Summary 
Information for Similar 
Biotherapeutic Product 
(SIB) template 
The purpose of the SIB was not mentioned in 
section 2.1 
Proposed: 
 Information in the WHO QIS template covering forward may 
be used for drafting the purpose. 
It is also stated that the QIS provides an accurate record of 
technical data in the product dossier (PD) at the time of 
prequalification and thereafter serves as an official reference 
document during the course of GMP inspections, variation 
assessments and requalification assessments as performed by 
WHO. It represents the final, agreed upon key information 
from the PD review.  
 
 Appendix 2 of the proposed guideline contains In order to avoid confusion, the PASIB should be removed 
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a template of the Public Assessment Summary 
Information for Similar Biotherapeutic 
Product and not a SIB template as stated.  
 
The format and content of the Public 
Assessment Summary Information for Similar 
Biotherapeutic Product appended is the same 
as that of the Public Assessment Summary 
Information for Biosimilars (PASIB) 
published by the IPRP Biosimilar Working 
Group (IPRP-BWG).  
 
According to the IPRP website, the PASIB 
template is intended to assist National 
Regulatory Authorities (NRAs) in making 
available a summary of the assessment 
(review) of biosimilar applications in their 
jurisdiction / country in a common language, 
for example, in English. For NRAs who 
already publish assessment reports following 
the review of medicinal product applications 
in their country, these are often in the local 
language and as a result are not easily 
accessible to the wider (global) community.  
 
The PASIB is intended to increase 
transparency and to facilitate the transition 
from a local assessment report to one prepared 
in the English language. The PASIB includes 
key information and summarized details of the 
biosimilar review. The template and it’s use 
were designed to reduce local translation 
effort by the NRA to a minimum and should 
be completed in accordance with local 
requirements, however, if found to be helpful 
the applicant / sponsor for the biosimilar can 
populate data elements of the document in 
and a SIB attached as appendix 2. In drafting a SIB, the 
PASIB template may provide useful information for inclusion 
in the SIB as applicable to Uganda’s situation. For example, 
the PASIB requires inclusion of information on 
interchangeability and extrapolation of indications, areas that 
are not clear in the proposed biosimilar guideline.  
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English, as part of the process. 
 
 
a) Formal Meetings Between the FDA and Sponsors or Applicants of Bs UFA Products; Guidance for Industry; Draft 
Guidance, June 2018, U.S.FDA, accessed on 28/02/19 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM609662.pdf?ut
m_campaign=FDA%20Issues%20Draft%20Guidance%20for%20Industry%3A%20Formal%20Meetings%20Betwe
en%20the%20Food%20and%20Drug%20Administration&utm_medium=email&utm_source=Eloqua 
b) Pre-authorisation guidance; EMA; accessed on 28/02/19 https://www.ema.europa.eu/en/human-
regulatory/marketing-authorisation/pre-authorisation-guidance 
c) Pre-submission meetings with TGA, March 2018, accessed on 28/02/19 https://www.tga.gov.au/publication/pre-
submission-meetings-tga 
d) Pre-submission meetings; WHO Prequalification, accessed on 28/02/19 
https://extranet.who.int/prequal/search?search_api_views_fulltext=presubmission&op=search 
e) WHO QIS Template, July 2017, accessed on 01/03/19  https://extranet.who.int/prequal/key-resources/documents/Q 
f) The International Pharmaceutical Regulators Forum website, accessed on 01/03/19 https://www.i-p-r-f.org 
 
1.1 Recommendations: Other 
A. The proposed guideline should be finalized as soon as possible and made available on the NDA 
website.  
 
B. Policy on interchangeability and/or substitution 
The proposed biosimilar guidelines should clearly state NDA’s position on interchangeability and/or 
substitution. A clear definitive policy on interchangeability will ensure better outcomes for patients 
without placing inordinate burden on health care professionals. Below are the statements on 
interchangeability in the reviewed guidelines. 
 
Uganda EU South Africa U.S.A WHO 
Interchangeability, 
substitution and 
switching are 
defined in the 
proposed guideline 
EMA does not regulate 
interchangeability, switching and 
substitution of a reference 
medicine by its biosimilar.  
These fall within the remit of EU 
Biosimilars are not 
considered to be 
interchangeable with the 
reference medicine or other 
medicines of the same class. 
In U.S.A, a biosimilar may 
be substituted for the 
reference product without 
intervention of the health 
care provider who 
Not applicable. 
 
It  is stated that important 
issues associated with the 
use of SBPs including 
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but are not 
addressed anywhere 
else in the 
guideline. NDA’s 
position on 
interchangeability is 
unknown.  
Member States  
Substitution in terms of 
Section 22F (Generic 
substitution) of Act 101 of 
1965 (i.e. the practice by 
with a different product to 
that specified on the 
prescription is dispensed to 
the patient without the prior 
informed consent of the 
treating physician) does not 
apply to Biosimilars. 
prescribed the reference 
product.  
 
However, general 
scientific issues relating to 
the demonstration on 
interchangeability are not 
included in the reviewed 
guidelines are addressed 
separately on the U.S. 
FDA website.  
interchangeability and 
substitution of RBP with 
SBP, need to be defined 
by NRAs and are 
therefore not elaborated in 
the guideline. 
 
 
C. Possibility of extrapolation of efficacy and safety from one therapeutic indication to 
another 
The proposed NDA biosimilar guideline should include information on extrapolation as intended 
to be addressed by NDA and not only include a reference WHO guideline. The U.S. FDA 
guidelines provide useful information on examples of scientific justification that may be 
provided. Also, the reflection paper prepared by the IPRF Biosimilars Working Group (BWG)* 
is a useful document in understanding the current thinking of various regulatory authorities of 
different regions with respect to the extrapolation of indications from reference product to the 
biosimilar during the development of these products. Below are the statements from reviewed 
guidelines. 
 
Uganda EU South Africa U.S.A WHO 
No clear statement on 
extrapolation of biosimilar 
from one indication to 
another. Reference made to 
WHO guideline.  
If biosimilarity has been 
demonstrated in one 
indication, extrapolation to 
other indications of the 
reference product could be 
acceptable with appropriate 
justification. 
 
Extrapolation should be 
considered in the light of the 
totality of data, i.e. quality, 
Where the clinical 
effects of the medicine 
have been shown to be 
related to the same mode 
of actions and the safety 
and efficacy of the 
biosimilar medicine and 
the reference product 
have been demonstrated 
for a particular clinical 
indication, it  may be 
If the proposed product 
meets the statutory 
requirements for licensure 
as a biosimilar product 
under section 351(k) of the 
PHS Act based on, among 
other things, data derived 
from a clinical study or 
studies sufficient to 
demonstrate safety, purity, 
and potency in an 
If similarity between the 
SBP and the RBP has 
been convincingly 
demonstrated, and if the 
manufacturer can provide 
scientific justification for 
such extrapolation, the 
SBP may be approved for 
use in other clinical 
indications for which the 
RBP is used but which 
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non-clinical and clinical data. 
 
Extrapolation of 
immunogenicity from the 
studied indication /route of 
administration to other uses of 
the reference product should 
be justified. 
possible to extrapolate 
these data to other 
indications of the 
reference product that 
have not been 
independently and 
specifically studied for 
the biosimilar medicine 
in clinical trials. 
 
The applicant should 
provide convincing 
motivation and in detail 
discuss the scientific 
basis and the risk/benefit  
for the proposed 
extrapolated clinical 
indications. 
 
Safety and immunogenicity 
of the biosimilar product 
must be sufficiently 
characterized. 
appropriate condition of 
use, the applicant may seek 
licensure of the proposed 
product for one or more 
additional conditions of 
use for which the reference 
product is licensed. 
 
However, the applicant 
would need to provide 
sufficient scientific 
justification for 
extrapolating clinical data 
to support a determination 
of biosimilarity for each 
condition of use for which 
licensure is sought. 
have not directly been 
tested in clinical trials. 
 
Any significant 
differences between the 
SBP and the chosen RBP 
detected during the 
comparability exercise 
would indicate that the 
products are not similar 
and that more extensive 
nonclinical and clinical 
data may be required to 
support the application for 
licensing. 
 
*IPRP Biosimilars Working Group, June 16 2017; Reflection Paper on extrapolation of Indications in Authorization of 
Biosimilar Products, available at http://www.iprp.global/page/biosimilar-activities 
 
D. NDA website should include a separate list of registered biotherapeutic medicines and biosimilar 
products. Currently information on approved biotherapeutics and biosimilars is not readily 
accessible. Alternatively, the current online drug register may be revised to provide for 
therapeutic and product class.    
 
E. NDA should consider drafting information for patients and health care providers about 
biosimilars in order to increase their understanding of these products and confidence in them. 
The EMA and U.S.FDA websites have detailed information intended to increase understanding 
of these products and build confidence.  
a. In order to increase biosimilar uptake, it is stated in the WHO bulletin Kang et al (2018) 
that regulatory authorities should make an effort to communicate with, and educate, all 
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stakeholders, including patients, about biosimilars and their approval. The provision of 
such information contributes to better transparency and increase public trust in 
biosimilars.  
WHO bulletin; Hye-Na Kang & Ivana Knexevic; 2018; Regulatory evaluation of biosimilars throughout their 
product life-cycle; accessed on 26/02/19 http://www.who.int/bulletin/volumes/96/4/17-206284/en/ 
 
Patient and health care provider biosimilar information on the EMA website: 
EMA has not only published guidance and guidelines for biosimilar manufacturers/developers, but has 
also published information for patients and health care professionals to improve understanding of 
biosimilar medicines in the EU. The following information for patients and healt h care professionals is 
currently published:  
• An animated video for patients explaining key facts on biosimilar medicines and how EMA 
works to ensure that they are safe and effective as their reference biological medicines. The 
video is currently available in the following European languages: Dutch, English, French, 
German, Italian, Polish, Portuguese and Spanish. 
• An information guide for patients published by the European Commission explaining what 
biosimilar medicines are, how they are developed and approved in the EU and what patients can 
expect in terms of availability and safety. The guide is available in 23 official EU languages. 
• Biosimilars in the EU – Information guide for health care professionals. The guide is available in 
eight (8) languages; English, Dutch, French, German, Italian, Polish, Portuguese and Spanish.  
In addition, the EU publishes summaries of the European public assessment reports (EPARs) for each of 
the approved biosimilars. The reports expla in how EMA assessed the medicine to recommend its 
authorization in the EU and its conditions of use. Product information which provides practical 
information for health care providers and patients is also published for each approved biosimilar. The 
product information includes summary of product characteristics, labelling information and package 
insert or patient information leaflet (PIL).  
(EMA website: Biosimilar medicines: Overview; https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-
medicines-overview) 
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Patient and health care provider biosimilar information on the U.S.FDA website  
U.S.FDA published a Biosimilars Action Plan (BAP) to provide information about the key actions the 
agency is taking to encourage innovation and competition among biologics and the development of 
biosimilars. 
Also, through its Center of Drug Evaluation and Research (CDER), the FDA offers a variety of patient 
and prescriber outreach materials including:  
a) videos [The Promise of Biosimilars, The Basics of Biosimilars, The Concept of 
Interchangeability, The Biosimilar Development Process, and Analytical Data for Biosimilar 
Products];  
b) Fact sheets [Biological Product Definitions, Biosimilar Product Regulatory Review and 
Approval, Prescribing Biosimilar Products, and Prescribing Interchangeable Products]; 
Infographics [Biosimilar Development Process, and What is a Biosimilar];  
c) stakeholder toolkit intended to help stakeholders promote FDA as a resource for information on 
biosimilars and interchangeable products and to encourage prescribers and patients to talk to 
each other about these medicines. The stakeholder kit includes: animated GIFs, website badges, 
print Ads, infocards, twitter posts and facebook/LinkedIn posts.  
The website also includes drop-in content e.g. newsletter articles for prescribers and patients related to 
biosimilars.  
The FDA offers online courses, webinars and presentations (FDA staff presentations) to he lp 
manufactures, the public and regulators worldwide learn more about biologics, biosimilars and 
interchangeable products. Product information, that is, prescribing information and any other related 
information e.g. press releases is available for each of the approved biosimilar medicines.  
(U.S.FDA website: Biosimilars; 
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeut
icbiologicapplications/biosimilars/default.htm) 
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